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SUMMARY 52 
 Mycobacterial cell wall lipids bind the conserved CD1 family of antigen-presenting 53 
molecules and activate T-cells via their T-cell receptors (TCRs). Sulfoglycolipids (SGLs) are 54 
uniquely synthesized by Mycobacterium tuberculosis, but tools to study SGL-specific T-cells in 55 
humans are lacking.  We designed a novel hybrid synthesis of a naturally occurring SGL, 56 
generated CD1b tetramers loaded with natural or synthetic SGL analogs, and studied the 57 
molecular requirements for TCR binding and T-cell activation.  Two T-cell lines derived using 58 
natural SGLs are activated by synthetic analogs independently of lipid chain length and 59 
hydroxylation but differentially by saturation status.  By contrast, two T-cell lines derived using 60 
an unsaturated SGL synthetic analog were not activated by the natural antigen.  Our data 61 
provide a bioequivalence hierarchy of synthetic SGL analogs and SGL-loaded CD1b tetramers.  62 
These reagents can now be applied to large-scale translational studies investigating the 63 
diagnostic potential of SGL-specific T-cell responses or SGL-based vaccines. 64 
 65 
KEYWORDS  66 
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INTRODUCTION 68 
 Mycobacterium tuberculosis (M.tb) caused over nine million infections and 1.4 million 69 
deaths worldwide in 2015, making it the leading infectious cause of mortality (WHO, 2016). The 70 
waxy cell wall of M.tb contains many unique lipids that are recognized by human T-cells when 71 
bound to conserved CD1 molecules at the surface of antigen-presenting cells (Beckman et al., 72 
1994). Sulfoglycolipids (SGLs) are a family of cell wall lipids found only in M.tb that consist of a 73 
sulfotrehalose core with up to four acyl chains that differ in length and composition (Goren, 74 
1970). Among the acylations there is typically a phthioceranic or hydroxyphthioceranic acid with 75 
multiple methyl groups (Goren et al., 1971; Layre, Paepe, et al., 2011).  SGLs were first 76 
described in virulent M.tb, and SGL synthesis is regulated by PhoP, a transcription factor 77 
expressed by M.tb that has a well-established role as a virulence factor (Goren, 1970; Chesne-78 
Seck et al., 2008; Lee et al., 2008).  Later studies allowed identification and characterization of a 79 
family of sulfoglycolipids (acylated trehalose 2’-sulphate) that were detectable only in M.tb and 80 
their amounts correlated with the relative virulence in guinea pigs (Goren, Brokl and Schaefer, 81 
1974).  Presence of SGL in virulent bacteria, but not in environmental strains or vaccine strains, 82 
is also supported by lipidomic profiling of the cell wall of M.tb and the M. bovis BCG vaccine 83 
strain (Layre, Sweet, et al., 2011).  The preferential expression of SGLs by pathogenic M.tb 84 
strains suggests that SGL-specific T-cells could be harnessed to develop novel lipid-based 85 
strategies for specifically diagnosing or treating tuberculosis.  For such clinical applications, the 86 
availability of contaminant-free, chemically well-defined antigens is crucial (Gilleron et al., 2004).  87 
Diacylated SGL (Ac2SGL) is one of only eight cell wall lipids from M.tb that have been 88 
identified as CD1-presented antigens for human T-cells (Beckman et al., 1994; Sieling et al., 89 
1995; Moody et al., 1997; Gilleron et al., 2004; Layre et al., 2009).  Proof-of-principle that 90 
Ac2SGL is presented by CD1b to T-cells was obtained using two in vitro derived T-cell clones 91 
named Z4B27 and Z4A26 derived from a healthy donor with latent M.tb infection (Gilleron et al., 92 
2004). In addition, recall responses to Ac2SGL by primary lymphocytes isolated from patients 93 
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depends on prior exposure to M.tb but is not affected by a history of vaccination with BCG 94 
(Gilleron et al., 2004). This is in contrast to the tuberculin skin test (TST), which is commonly 95 
used to diagnose M.tb infection in humans but is limited by false positive responses in BCG-96 
vaccinated populations (Farhat et al., 2006).  Further translational work on Ac2SGL-specific T-97 
cells has been hampered for two main reasons.  First, Ac2SGLs exist at low abundance in the 98 
M.tb cell wall, so purifying a sufficient quantity to perform a large-scale clinical study is 99 
economically and logistically prohibitive.  Characteristic markers for SGL-specific T-cells other 100 
than an antigen-specific T-cell receptor (TCR) are not known, so there are no tools to facilitate 101 
their identification in ex vivo blood or tissue samples.  102 
Synthetic analogs of Ac2SGL have been reported previously, and their biological potency 103 
compared to the natural compounds has been assessed using Z4B27 and Z4A26 T-cell clones 104 
(Guiard et al., 2008, 2009; Gau et al., 2013). These data have revealed that the presence of a 105 
hydroxyl group, the number of C-methyl substituents on the acyl chains, the configuration of the 106 
chiral centers, and the respective localization of the two different acyl chains on the sugar 107 
moiety govern TCR recognition and T-cell activation (Guiard et al., 2009). Comparing C16, C24, 108 
and C32 long chain tri-methylated fatty acids revealed increased stimulatory capacity of analogs 109 
with the longer alkyl chain lengths (Gau et al., 2013). These findings were supported by a 110 
crystal structure which showed that part of the Ac2SGL lipid tail is exposed to the solvent above 111 
the binding plane, explaining why the methyl groups on the tail of the lipid are important for 112 
antigenicity (Garcia-Alles et al., 2011).  113 
We designed a novel hybrid synthesis of a naturally occurring Ac2SGL by combining an 114 
iterative conjugated addition protocol and a lithiation/borylation protocol. This method 115 
substantially increases the yield of hydroxyphthioceranic acid, a key antigenic determinant of 116 
Ac2SGL.  An important tool to study antigen-specific polyclonal T-cells directly ex vivo is by a 117 
fluorescent probe, called a tetramer, which binds selectively to antigen-specific T-cells within a 118 
mixed population.  Here, we generated CD1b tetramers loaded with natural and two synthetic 119 
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versions of Ac2SGL antigens and used these reagents to study human Ac2SGL-specific T-cells. 120 
Our data reveal the fine specificity of human T-cells for Ac2SGL and demonstrate bio-121 
equivalence of one new synthetic analog and natural Ac2SGL, which will permit extensive 122 
translational studies of Ac2SGL-specific T-cells.    123 
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RESULTS 124 
Natural and Synthetic Ac2SGL Antigens 125 
Ac2SGL purified from M.tb (referred to as natural Ac2SGL) is a family of molecules 126 
containing a sulfotrehalose core, which is diacylated with a phthioceranoyl or a 127 
hydroxyphthioceranoyl group at the 3 position and a palmitoyl or stearoyl group at the 2 position 128 
(Goren et al., 1971; Layre, Paepe, et al., 2011). The hydroxyphthioceranoyl group varies in alkyl 129 
chain length (C22-C42) and in the number of methyl groups, ranging from 2 to 11 (Layre, 130 
Paepe, et al., 2011).  The combined effect of positional, chain length, and methylation variants 131 
leads to thousands of known molecular SGL variants cataloged in the MycoMass database and 132 
other sources (Layre, Sweet, et al., 2011; Sartain et al., 2011).  Four different analogs differing 133 
only in the structure of the alkyl chain in position 3 of the sulfotrehalose core were used in this 134 
study (Fig 1A).  The first molecule has a sulfotrehalose core with a palmitoyl and a 135 
tetramethylated unsaturated fatty acid (compound 21c of reference (Gau et al., 2013)), which 136 
we will refer to as SL37 Ac2SGL (Fig. 1A). Two additional compounds, SL27 (SGL12 of 137 
reference (Guiard et al., 2009)) and SL29 Ac2SGL (SGL8 of reference (Guiard et al., 2009)), 138 
have the same sulfotrehalose core with a palmitic acid linked as in SL37 Ac2SGL, but the 139 
tetramethylated fatty acid is eight carbons shorter. SL27 Ac2SGL is further distinguished from 140 
SL29 due to the unsaturation on the first methyl group in the chain (Fig 1A).  The fourth 141 
molecule, called AM Ac2SGL exactly mimics the structure of one of the compounds in the 142 
natural Ac2SGL mixture, and is reported here. 143 
The main challenge in synthesizing a compound that is chemically identical to the 144 
natural species is the stereoselective preparation of hydroxyphthioceranic acid.  Geerdink et al. 145 
previously published a first total synthesis of hydroxyphthioceranic acid containing tetra-acylated 146 
SGL by applying copper-catalyzed asymmetric conjugate addition and allylic substitution as the 147 
key steps (Geerdink and Minnaard, 2014). Soon thereafter the groups of Schneider and 148 
Aggarwal reported syntheses of hydroxyphthioceranic acid based on asymmetric hydrogenation 149 
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 8 
and a lithiation/borylation/protodeborylation strategy, respectively (Pischl et al., 2013; Rasappan 150 
and Aggarwal, 2014). Still, these approaches comprise a large number of steps.  We designed a 151 
novel hybrid synthesis of hydroxyphthioceranic acid by combining the efficient asymmetric Cu-152 
catalyzed iterative conjugated addition protocol with the lithiation/borylation strategy in the later 153 
stage of synthesis (Fig. 1B). This strategy was effective and led to a higher yield and more 154 
efficient synthesis of hydroxypthioceranic acid. To subsequently assemble a fully synthetic 155 
Ac2SGL that recapitulates a natural compound, hydroxyphthioceranic acid was regioselectively 156 
esterified to the trehalose core using Yamaguchi conditions (Fig. 1C). The existing route could 157 
be improved, as it turned out that protection of the hydroxyl group in hydroxyphthioceranic acid 158 
was not required for the esterification to trehalose (Geerdink and Minnaard, 2014). 159 
Regioselective 2'-O-sulfation was carried out, followed by removal of the benzylidene acetals 160 
and TCE group using a combination of Pd(OH)2-/C and Pd-/C leading to the final compound, 161 
termed AM Ac2SGL. The structures of the compounds were confirmed by NMR and mass 162 
spectrometry (STAR Methods).  Thus, we generated pure reagents in high yield that would 163 
allow us to probe the structural features required for antigen recognition by T-cells. 164 
 165 
Generation of Ac2SGL -specific tetramers and T-cell lines 166 
 We next used natural and synthetic Ac2SGL preparations to generate CD1b-Ac2SGL 167 
tetramers that would enable us to sort and expand T-cells specific for these lipid antigens.  168 
CD1b-Ac2SGL tetramers are multimers of CD1 proteins that are fluorescently labeled and 169 
loaded with Ac2SGL to take advantage of high avidity to bind polyclonal T-cells even when 170 
present in low numbers of total blood cells.  This powerful technique can be used to detect 171 
antigen specific T-cells in patients, isolate T-cell clones of interest, or investigate T-cell fine 172 
specificity for structurally related antigens.  Based on a long term goal of detecting SGL-specific 173 
T-cells in large cohorts of tuberculosis patients, we first generated CD1b tetramers loaded with 174 
natural Ac2SGL by adapting our recently published method for generating human CD1b 175 
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 9 
tetramers (Kasmar et al., 2011). Subsequently, peripheral blood mononuclear cells (PBMC) 176 
from a subject with latent tuberculosis were stained with the tetramer along with markers to label 177 
T-cells and cell viability (Figure 2A, left).  Even though we did not yet confirm that the tetramers 178 
were sufficiently loaded, we detected a rare population (0.008%) of T-cells that stained with 179 
CD1b-natural Ac2SGL tetramer.  These T-cells were sorted and expanded in vitro. We named 180 
the resulting T-cell line A01 and noted that 64% of A01 T-cells stained with CD1b-natural 181 
Ac2SGL tetramer (Figure 2A, center).  These results suggest stable loading of CD1b with natural 182 
Ac2SGL.  We used an antibody against the CD4 co-receptor to discover that the majority of 183 
Ac2SGL-specific T-cells within the A01 T-cell line did not express CD4 (Figure 2A, right).  These 184 
results are in contrast to mycobacterial glucose monomycolate-specific T-cells, which commonly 185 
express CD4 (Kasmar et al., 2011; Van Rhijn et al., 2013).  We generated another T-cell line 186 
(A05) specific for natural Ac2SGL by first stimulating PBMC with the antigen in the presence of 187 
monocyte-derived dendritic cells and subsequently sorting using CD1b-natural Ac2SGL tetramer 188 
(Figure 2B, left).  We noted that 92% of A05 T-cells stained with CD1b-natural Ac2SGL tetramer 189 
(Figure 2B, center) and predominantly express the CD4 co-receptor (Figure 2B, right).  Further, 190 
we generated SL37 Ac2SGL-loaded CD1b tetramers and isolated SL37 Ac2SGL-specific T-cells 191 
from two additional subjects with latent tuberculosis to create two additional T-cell lines, named 192 
56SL37 and 58SL37, one from each subject. We noted that these two T-cell lines differed with 193 
respect to the expression of the CD4 co-receptor (Figures 2C and 2D).  These results validate 194 
CD1b tetramers loaded with natural Ac2SGL or SL37 Ac2SGL and describe four new SGL-195 
specific T-cell lines. 196 
 197 
T-cell specificity for natural and synthetic Ac2SGL analogs 198 
We then explored the reactivity of the newly derived T-cell lines to natural and synthetic 199 
SGLs. We noted that natural Ac2SGL and AM Ac2SGL stimulated A01 with half-maximal 200 
effective concentration (EC50) of 0.04 µg/ml and 0.006 µg/ml respectively in an IFN- ELISPOT 201 
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assay (Figure. 3A). Similarly, AM Ac2SGL is a potent antigen for A05, with an estimated EC50 202 
value of 0.0006 µg/mL (Figure 3A). However, SL37 Ac2SGL was a much less potent antigen for 203 
both A01 and A05, with an average EC50 of 0.11 g/ml. In addition, SL27 Ac2SGL, which has a 204 
shorter methylated carbon chain than SL37 Ac2SGL, had an average EC50 of 0.01 g/ml, while 205 
SL29 Ac2SGL, which lacks the unsaturation in methylated carbon chain, has an EC50 of 0.009 206 
g/ml, similar to that of AM Ac2SGL (Figure 3B). Collectively, the low EC50 estimates using AM 207 
Ac2SGL and SL29 Ac2SGL to activate both the A01 and A05 T cell lines demonstrate the 208 
importance of using fully saturated analogs similar to that present in natural Ac2SGL to induce 209 
strong activation of the T-cells.  Further, these data suggest that the extra methylations and 210 
hydroxyl group present in AM Ac2SGL and lacking in SL29 Ac2SGL are not required to 211 
reproduce the activity of the native mixture (Figure 1A).  212 
The T-cell lines C56SL37 and C58SL37, which were derived using SL37 Ac2SGL-loaded 213 
tetramers, were activated by SL37 Ac2SGL as expected, and this was blocked by anti-CD1b 214 
(Figure 3C and data not shown). However, neither AM Ac2SGL nor M.tb lipid extract containing 215 
natural Ac2SGL were stimulatory for C56SL37 and C58SL37. Because the three Ac2SGL 216 
variants tested here share an identical sulfated trehalose head group and 2-palmitoylation, the 217 
data confirm that T-cells display specificity for the acylation at the 3 position of the Ac2SGL 218 
synthetic analogs (Guiard et al., 2009; Gau et al., 2013). Finally, we stained A01 using CD1b 219 
tetramers treated with natural Ac2SGL or AM Ac2SGL to validate its ability to recognize each 220 
lipid variant. Tetramers treated with natural Ac2SGL or the synthetic analog AM Ac2SGL stained 221 
equivalently sized populations of the A01 and A05 T-cell lines (Figure 3D).  Together, these 222 
data suggest that AM Ac2SGL and SL29 Ac2SGL are bio-equivalent to natural Ac2SGL and 223 
provide biological validation of the stereoselective preparation of hydroxyphthioceranic acid 224 
described above (Figure 1B).   225 
 226 
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CD1b surface point mutants abrogate T-cell activation by Ac2SGL 227 
Next, we asked whether mutations in the CD1b binding surface would influence 228 
recognition of Ac2SGLs. We generated a library of mutations in the 1 and 2 domains of CD1b 229 
to selectively modify the surface available for contacting the TCR (Figure 4A).  The mutations 230 
are not predicted to change the antigen-binding cleft. C1R cells were transduced with the 231 
mutant CD1b constructs and used as antigen presenting cells for T-cells.  Importantly, all of 232 
these transfectants expressed similar levels of CD1b at the cell surface (Figure 4B).  We 233 
examined the effect of each of these mutations on activation of A01 and A05 T-cell lines in 234 
response to AM Ac2SGL. Amino acid D83 markedly reduced activation of both A01 and A05 T-235 
cell lines (Figure 4C). Additionally, we noted that amino acids Y151, E80, and V72, which are 236 
located near the center of the CD1b platform near the site of the expected SGL headgroup 237 
protrusion, significantly abrogated T-cell activation of the A01 but had more modest effects on 238 
A05 (Figure 4C). These data emphasize the critical nature of centrally located residues in both 239 
the 1 and 2 domains of CD1b on T-cell recognition of SGLs (Garcia-Alles et al., 2011). 240 
 241 
Synthetic Ac2SGL analogs are recognized by diverse T-cell receptors 242 
Finally, we used commercial immunosequencing or single-cell multiplex PCR to obtain 243 
the sequences for the TCR 𝛼  and 𝛽  chain of A01, C56SL37, and C58SL37. We further 244 
confirmed the TCR sequence by staining all three lines with the predicted anti-TCR V𝛽 antibody 245 
(data not shown).  We found no overlap in dominant TCR sequences among the three lines 246 
(Table 1).  Unlike recent results with mycobacterial glucose monomycolate-reactive clones, this 247 
survey of three Ac2SGL-specific TCRs failed to demonstrate conservation of TCRs that bind 248 
antigens with identical head groups but differ in the composition of only one of two lipid tails.  To 249 
test whether the TCR alone is sufficient to convey antigen specificity, we transduced Jurkat 76 250 
cells that lack CD4 and CD8 co-receptor molecules with the dominant C58SL37 TCR 𝛼 and 𝛽 251 
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chain. We tested two TCR-transduced clones that stained with SL37 Ac2SGL-loaded tetramers, 252 
but not with mock loaded tetramers (Figure 5A). These data confirm the identity of the dominant 253 
clone within the C58SLS37 T-cell line.  Stimulation with CD1b-transfected, but not CD1a-254 
transfected antigen presenting cells, activated TCR-transduced cells in the presence but not in 255 
the absence of SL37 Ac2SGL (Figure 5B).  Together, these data reveal that TCR interaction with 256 
CD1b and SGL antigen is sufficient to mediate T-cell activation.  257 
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DISCUSSION 258 
The discovery that human T-cells recognize bacterial lipid antigens bound to CD1 259 
proteins opened new areas of investigation with potential applications in pathogen-specific 260 
immunity (Porcelli, Morita and Brenner, 1992; Beckman et al., 1994).  However, key reagents 261 
and tools to conduct studies in human populations have been lacking.  Here, we describe four 262 
main results that will advance translational studies of CD1-restricted T-cells in tuberculosis 263 
patients.  First, we report a new hybrid synthesis strategy for key antigenic determinants of 264 
Ac2SGL that resulted in substantially higher yields of synthetic Ac2SGL than previous schemes.  265 
Second, we provide chemical and immunologic data demonstrating the equivalence of the new 266 
synthetic Ac2SGL compound to the natural ligand. Third, we report the generation and validation 267 
of Ac2SGL-loaded CD1b tetramers, a new tool that will allow us to probe the phenotypes and 268 
functions of Ac2SGL-specific T-cells ex vivo.  Finally, we provide insights in cross-reactivity 269 
patterns among human Ac2SGL-specific T-cell lines that will guide choices concerning the 270 
development of synthetic Ac2SGL analogs into vaccine components.  271 
Because SGLs are normally produced in many hundreds of forms, but will be developed 272 
as vaccines and recall reagents using chemically simplified versions, understanding whether 273 
multiple forms are bioequivalent is essential. Our data show that synthetic analogs of SGLs are 274 
not equivalent, and understanding the specific chemical basis of divergence is important. 275 
Previous studies have demonstrated that phthioceranic acid and hydroxyphthioceranic acid are 276 
key antigenic determinants of Ac2SGL, but synthesis of these complex lipids required multiple 277 
steps and were typically not of sufficient yield to enable large scale clinical studies (Gilleron et 278 
al., 2004; Guiard et al., 2009; Geerdink, Horst, Lepore, Mori, Puzo, Anna K. H. Hirsch, et al., 279 
2013; Geerdink and Minnaard, 2014; Rasappan and Aggarwal, 2014). The novel hybrid 280 
synthesis scheme we present here is much simpler and results in yields that enable validation of 281 
a new immunologic tool to probe SGL-specific human T-cell responses ex vivo. The A01 and 282 
A05 T-cell lines that we isolated based on recognition of natural Ac2SGL cross-react strongly 283 
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with AM Ac2SGL, a synthetic molecule that is a component of the natural Ac2SGL mixture that 284 
includes eight methylated carbons on the hydroxyphthioceranic acid and corresponds to the 285 
major acyl form at m/z 1249.9. It also cross-reacts strongly with SL29 Ac2SGL, which has a fully 286 
saturated tetramethylated phthioceranic acid.  By contrast, A01 reacts weakly with SL37 287 
Ac2SGL, a molecule that is not identical to any form of naturally occurring Ac2SGL. Further, we 288 
show that T-cell lines from two different blood donors that were isolated based on recognition of 289 
SL37 Ac2SGL are unable to recognize natural Ac2SGL. Thus, even though the Z4B27 T-cell 290 
clone originally reported to recognize natural Ac2SGL was broadly cross reactive and 291 
recognized nature-identical and modified versions of Ac2SGL, this is not a general rule and has 292 
implications for the use of synthetic Ac2SGL in future designs of vaccines against tuberculosis 293 
(Gilleron et al., 2004).   294 
Our findings have immediate relevance for the development of novel whole cell and 295 
subunit vaccines for tuberculosis.  MTBVAC is an attenuated strain of M.tb that recently 296 
completed Phase I clinical trials and has entered efficacy testing (Spertini et al., 2015). 297 
MTBVAC contains inactivating mutations in fadD26 and phoP, thus it would not be expected to 298 
express SGLs and induce Ac2SGL-specific T-cell responses (Arbues et al., 2013). Induction and 299 
expansion of SGL-specific T-cells could be measured using tetramers and used as a surrogate 300 
marker of infection with M.tb in efficacy studies of MTBVAC.  Another approach would be to 301 
consider vaccinating with lipid antigens themselves.  CD1-restricted T-cells have anti-bacterial 302 
effector functions and lyse M.tb-infected target cells in vitro (Stenger et al., 1997; Rosat et al., 303 
1999; Busch et al., 2016).  Humanized mouse models have shown that these cells can provide 304 
protection against M.tb challenge in vivo (Zhao et al., 2015). In a recently published guinea pig 305 
vaccination model, natural and SL37 Ac2SGL containing liposomes conferred modest protection 306 
to M.tb challenge (Larrouy-Maumus et al. 2017). These results may reflect suboptimal cross-307 
reactivity with SGL antigens present in M.tb and could be improved if T-cells were primed using 308 
a different synthetic analog, such as AM or SL29 Ac2SGL.  Our data show that there is a human 309 
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T-cell repertoire for natural and synthetic forms of Ac2SGL, so it might be possible to use 310 
synthetic analogs other than SL37 to prime T-cells by immunization.  The high yields that are 311 
possible through the novel synthetic scheme we describe here should enable investigators to 312 
optimize vaccination strategies in small animal models by comparing various doses, routes, and 313 
formulations.  The immunogenicity of these vaccines in humans can then be evaluated using 314 
the SGL-loaded CD1b tetramers. 315 
The newly developed Ac2SGL-loaded CD1b tetramers will be useful in probing the 316 
functions of Ac2SGL-specific T-cells because it is generally not known which functional classes 317 
exist among lipid-specific T-cells in vivo. Tetramer staining can be used in combination with 318 
staining for markers of T-cell function, including cytokine production, or to isolate single Ac2SGL-319 
specific T-cells for RNA sequencing. Further, the TCR repertoire of Ac2SGL-specific T-cells can 320 
now be studied using tetramers. We describe three newly discovered TCRs here with different 321 
patterns of reactivity against natural and synthetic SGLs.  High throughput sequencing of T-cells 322 
that bind to tetramers loaded with natural or AM Ac2SGL could potentially lead to the 323 
identification of a highly relevant new population of invariant T-cells. It is worth noting that one of 324 
our T-cell clones contained a TRAV17 to TRAJ9 rearrangement. Though the CDR3 regions are 325 
markedly different, we have previously reported TRAV17 to TRAJ9 rearrangements among a 326 
group of CD1b and glucose monomycolate-specific T-cells that are called “LDN5-like T-cells” 327 
(Van Rhijn et al., 2014).  Thus, TRAV17 and TRAJ9 may be part of a general molecular pattern 328 
that is associated with CD1b recognition.  329 
We used CD1b point mutants to study the influence of specific residues located at the 330 
CD1b surface on T-cell activation and found that mutation of V72, E80, D83, or Y151 reduces T-331 
cell activation. This reduction could be caused by diminished direct interaction between these 332 
residues and the TCR. An alternative possibility is that these residues are required to “lock” the 333 
SGL antigen in the CD1b binding groove, so that lack of T-cell activation reflects a lack of 334 
antigen.  Supporting the latter model is the published crystal structure of CD1b bound to SL27 335 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
Ac2SGL, which reveals a dramatic conformational change and decreased groove volume 336 
compared to unloaded soluble CD1b in which E80 and Y151 are responsible for occluding the 337 
F’ entrance of the CD1B binding pocket (Garcia-Alles et al., 2011).  Further, the authors show 338 
that replacement of E80 and Y151 with alanine completely abrogated the activation of T-cell 339 
clone Z4B27 to both natural Ac2SGL as well as SL27 Ac2SGL.  These published data are 340 
consistent with our results and suggest shared molecular mechanisms underlie recognition of 341 
CD1b-presented SGL antigens from natural and synthetic sources.  Our data further implicate a 342 
role of D83 and V72 in T-cell recognition of natural Ac2SGL that may differ from SL27 Ac2SGL. 343 
 Our findings may also have implications for the improved diagnosis of M. tb infection in 344 
humans.  The current standard for the diagnosis of latent tuberculosis infection is the IFN- 345 
release assay (Pai et al., 2014). This assay detects memory T-cell responses to ESAT-6 and 346 
CFP-10, two secreted proteins that are specific to M. tb.  While this test has improved specificity 347 
over the traditional tuberculin skin test (TST), neither test accurately predicts which patients will 348 
eventually develop active disease.  We recently published that T-cell responses to 349 
mycobacterial proteins and lipids are poorly correlated in a South African cohort, revealing the 350 
complementary nature of immunity to these two classes of antigens (Seshadri et al., 2015). The 351 
data presented in the current manuscript suggest measuring SGL-specific T-cell responses 352 
using tetramers could improve existing diagnostic algorithms by providing complementary 353 
information.  Unlike MHC tetramers, SGL-CD1b tetramers can be applied independently of 354 
genetic background because CD1 genes are structurally non-polymorphic (Han et al., 1999). 355 
SGL-loaded CD1b tetramers could also be used to detect SGL-specific T-cell responses in the 356 
blood or lungs of patients with suspected active tuberculosis disease.  Recent data have 357 
revealed that T-cells specific for ESAT-6 and CFP-10 that expressed an activated phenotype 358 
was able to distinguish latent infection from active disease (Adekambi et al., 2015).  SGL-CD1b 359 
tetramers could similarly be incorporated into multi-parameter flow cytometry assays designed 360 
to measure the activation status of lipid-specific T-cells. 361 
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  362 
SIGNIFICANCE 363 
 Sulfoglycolipids (SGLs) are a class of bacterial cell wall lipid that is uniquely synthesized 364 
by Mycobacterium tuberculosis (M.tb) and recognized by human T-cells.  Determining whether 365 
synthetic SGLs are bioequivalent to the natural mixture is essential to developing them into 366 
clinical products.  We describe a new hybrid synthesis for key antigenic determinants of SGL 367 
that results in higher yields than previous schemes.  We also report a bioequivalence hierarchy 368 
of synthetic SGLs and the development of SGL-specific T-cell probes called tetramers.  These 369 
reagents can now be applied to large-scale translational studies investigating SGLs as vaccine 370 
agents or the diagnostic potential of SGL-specific T-cells.  371 
  372 
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 389 
FIGURE AND TABLE LEGENDS 390 
Figure 1. Diacylated sulfoglycolipid (Ac2SGL) antigens.  (A) Structures of natural Ac2SGL 391 
purified from M.tb and three synthetic forms that have been previously described: SL37 Ac2SGL, 392 
SL27 Ac2SGL, SL29 Ac2SGL. Synthesis of a fourth analog (AM Ac2SGL) is reported here. 393 
These compounds are used to probe the specificity of T-cell responses to Ac2SGL antigens. (B) 394 
Hybrid synthesis method for hydroxyphthioceranic acid consisting of an iterative conjugated 395 
addition and lithiation/borylation. TBDPS = tert-butyldiphenylsilyl, MOM = methoxymethyl, Pin = 396 
pinacolato. (C) Regioselective addition of hydroxyphthioceranoic acid to the trehalose core 397 
followed by 2’-O-sulfation and deprotection to yield AM Ac2SGL.   Validation of the compounds 398 
by mass and NMR spectrometry is shown in the STAR Methods.    399 
 400 
Figure 2. Generation of SGL-specific T-cell clones.  T-cell lines were generated from 401 
peripheral blood mononuclear cells (PBMC) by sorting rare T-cells that bound to Ac2SGL-loaded 402 
tetramers followed by in vitro expansion.  Specificity of the resulting T-cell lines was confirmed 403 
by staining with the same tetramer used in the sort and reveal greater than 100-fold enrichment 404 
of antigen-specific T-cells.  CD4 co-receptor expression was also examined using a specific 405 
antibody.  (A) A01 T-cell line lacks CD4 expression and was created after two rounds of in vitro 406 
expansion after sorting with natural Ac2SGL-loaded tetramers (red polygon). (B) A05 T-cell line 407 
expresses CD4 and was generated by first stimulating PBMC with natural Ac2SGL in the 408 
presence of monocyte-derived dendritic cells and sorting with natural Ac2SGL tetramer 409 
following in vitro expansion (red box) (C) 56SL37 T-cell line expresses CD4 and was created 410 
after multiple round of in vitro expansion and re-sorting using SL37 Ac2SGL-loaded tetramers 411 
(red box). (D) 58SL37 T-cell line generated in a manner similar to 56SL37 but lacks CD4 412 
expression.  Sorting data are representative of a single experiment, but tetramer staining of T-413 
cell lines was confirmed in two or more experiments.  414 
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 415 
Figure 3. Fine specificity of SGL-specific T-cell lines. (A) IFN- production by A01 and A05 416 
in response to titrating amounts of natural Ac2SGL, AM Ac2SGL, and SL37 Ac2SGL as 417 
measured by an IFN- ELISPOT. (B) IFN- production by A01 and A05 in response to titrating 418 
amounts of AM Ac2SGL, SL29 Ac2SGL, and SL27 Ac2SGL as measured by an IFN- ELISPOT. 419 
(C) IFN- production by C56SL37 in response to 5 g/ml SL37 Ac2SGL, AM Ac2SGL, or whole 420 
mycobacterial lipid extract. T-cell clone activation was blocked using the anti-CD1b antibody 421 
BCD1b.3 (10 g/ml).  (D) A01(left) and A05 (right) was stained with mock loaded CD1b tetramer 422 
(shaded histogram) or CD1b loaded with either natural or AM Ac2SGL (open histograms).  Data 423 
are representative of two or three independent experiments.  Error bars represent standard 424 
deviation of triplicate wells in an ELISPOT assay.  425 
 426 
Figure 4. Effect of CD1b point mutations on SGL antigen recognition. (A) Location of CD1b 427 
point mutations in stably transfected C1R cells. The figure is based on PDB entry 1GZP (Gadola 428 
et al., 2002). Substitutions at residues colored green did not show an effect on A05 T-cell 429 
activation, while residues colored yellow showed moderate inhibition, and residues colored red 430 
showed complete inhibition (B) Expression of CD1b by each of the transfected C1R cells. 431 
Isotype indicates staining with an isotype control antibody.  (C) IFN- production by A05 and 432 
A01 T-cell clone in the presence of AM Ac2SGL and transfected C1R cells. WT = wild type. 433 
Controls are shown in as white bars and CD1b mutants are shown as black bars.   Data are 434 
representative of three independent experiments with triplicate wells. Error bars represent SEM 435 
of triplicate wells.  436 
 437 
Figure 5. TCR transduction confers antigen specificity.  (A) Jurkat cells were transduced 438 
with the dominant TCR- and TCR- of C58SL37 and clones were isolated by limiting dilution.  439 
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Two independent clones, clone 2 and clone 9, were stained with SL37 Ac2SGL-loaded 440 
tetramers or mock loaded tetramers. (B) C1R cells (20,000) transfected with CD1a or CD1b 441 
were loaded with SL37 Ac2SGL, mixed with clone 2 cells (100,000) and incubated overnight 442 
before staining with an antibody against CD69 as a marker of T-cell activation. MFI = mean 443 
fluorescence intensity. Data are representative of four independent experiments.   444 
 445 
Table 1. TCRs expressed by SGL-specific T-cell clones. T-cell receptor gene usage, CDR3 446 
region amino acid sequence, of Ac2SGL and SL37 specific T-cell cones. Variable and joining 447 
gene segment names were assigned using the International ImMunoGeneTics (IMGT) 448 
Database.   449 
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Table 1.  TCRs expressed by Ac2SGL-specific T-cell clones 450 
 451 
Clone TCR Variable CDR3 Joining 
A01  TRAV8-6 CAVKAGYSSASKIIF TRAJ3 
  TRBV12-4 CASKGKQGPEQFF TRBJ2-1 
56SL37  TRAV14 CAMRRGFQKLVF TRAJ8 
  TRBV4-1 CASSQALLTGSYEQYF TRBJ2-7 
58SL37  TRAV17 CATPNTGGFKTIF TRAJ9 
  TRBV6-2 CASSSPFRRASVGELFF TRBJ2-2 
 452 
  453 
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STAR Methods  454 
 455 
CONTACT FOR REAGENT AND RESOURCE SHARING 456 
 457 
Further information and requests for resources and reagents should be directed to and will be 458 
fulfilled by the Lead Contact, Chetan Seshadri (seshadri@u.washington.edu). 459 
 460 
Individuals seeking to establish SGL-loaded CD1b tetramers in their own labs will first need to 461 
complete a materials transfer agreement (MTA) with the NIH Tetramer Core Facility to receive 462 
soluble biotinylated CD1b monomers.  Synthetic AM Ac2SGL is available via the TB Vaccine 463 
Accelerator funded by the Bill & Melinda Gates Foundation upon request from Dr. Branch 464 
Moody.  465 
 466 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 467 
 468 
Human Studies:  469 
T-cell lines were derived from U.S. and South African adults with latent tuberculosis infection.  470 
The gender of these subjects is not reported and the samples were chosen cryopreserved 471 
repositories on the basis of convenience. Informed consent was obtained from all subjects.  472 
 473 
Approving Bodies:  474 
Blood was donated with informed consent by asymptomatic tuberculin positive subjects with no 475 
clinical or radiographic evidence of active tuberculosis, as approved by the institutional review 476 
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boards of the Lemuel Shattuck Hospital and Partners Healthcare.  The study was also approved 477 
by the IRB of the University of Washington and University of Cape Town.  478 
 479 
Primary T-cell Cultures:  480 
The cell line A01 was isolated from cryopreserved, CD14-depleted peripheral blood 481 
mononuclear cells (PBMC) from a South African adult with latent tuberculosis infection as 482 
defined by a positive QuantiFERON-TB Gold blood test. PBMC were thawed and washed in 483 
warm RPMI 1640 (Gibco, Waltham, MA) supplemented with 10% fetal bovine serum (Hyclone, 484 
Logan, UT) and 10 mL/mL Benzonase (Millipore, Billerica, MA) and enumerated using Trypan 485 
blue exclusion. T cell media consists of RPMI 1640 (Gibco, Waltham, MA) supplemented with 486 
10% fetal bovine serum (Hyclone, Logan, UT), 100 U/mL Penicillin and 100 mg/mL 487 
Streptomycin (Gibco, Waltham, MA), 55 mM 2-mercaptoethanol (Gibco, Waltham, MA), 0.3X 488 
Essential Amino Acids (Gibco, Waltham, MA), 60mM Non-essential Amino Acids (Gibco, 489 
Waltham, MA), 11mM HEPES (Gibco, Waltham, MA), and 800mM L-Glutamine (Gibco, 490 
Waltham, MA). PBMC were then plated in a 24-well plate at a density of three million cells per 491 
well in T cell media and allowed to rest overnight at 37°C in humidified incubators 492 
supplemented with 5% CO2. The following day, PBMC were washed and blocked with 50% 493 
human serum (Valley Biomedical, Winchester, VA) in PBS supplemented with 0.2% BSA 494 
(Sigma, St. Louis, MO) (FACS buffer) for 10 min at 4°C. The samples were washed twice with 495 
PBS and stained with Aqua Live/Dead stain (Life Technologies, Carlsbad, CA) according to the 496 
manufacturer’s instructions. Following two additional PBS washes, cells were resuspended in 50 497 
L FACS buffer and 1 uL of either mock loaded CD1b tetramer or Ac2SGL-loaded CD1b 498 
tetramer and incubated at room temperature for 40 minutes in the dark. Finally, cells were 499 
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stained with anti-CD3-Phycoerythrin-Texas Red (ECD) (Beckman Coulter, Brea, CA), washed 500 
twice in T cell media and filtered through a cell strainer tube (Falcon, Tewksbury, MA) prior to 501 
sorting. Tetramer-positive T cells were sorted using a FACS Aria II (BD, San Jose, CA) cell 502 
sorter equipped with 407nm, 488nm, and 641nm lasers. 503 
 Sorted T cells were washed and resuspended in T cell media supplemented with 10% 504 
human serum and divided among eight wells of a 96-well plate to create a T cell line. Irradiated 505 
PBMC (150,000 cells per well) were added as feeder cells along with phytohaemagglutinin 506 
(Remel, San Diego, CA) at a final concentration of 1.6 mg/ml. After two days in culture at 37oC, 507 
5% CO2, 10 mL natural IL-2 (Hemagen, Columbia, MD) was added to each well. Half the media 508 
was replaced every two days with T cell media supplemented with 10% human serum and 509 
natural IL-2. When the cell clusters were large and round (approximately after eight days of 510 
growth), they were pooled into a 24-well plate. After 10 days in culture, the cell line was 511 
screened by tetramer staining or functional response to Ac2SGL. We then further expanded the T 512 
cell line using a modified version of a previously published rapid expansion protocol (Riddell et 513 
al., 1992).  Briefly, 200,000 T cells were mixed with 5 million irradiated EBV-transformed B 514 
cells and 25 million irradiated PBMC as feeder cells in 25 ml T cell media. Anti-CD3 (clone 515 
OKT3) was added a final concentration of 30 ng/mL, and the mixture was incubated overnight at 516 
37oC, 5% CO2. The following day, recombinant IL-2 (rIL-2) (UWMC Clinical Pharmacy) was 517 
added to a final concentration of 50 U/mL. On day 4, the cells were washed twice in T cell media 518 
to remove OKT3, and fresh media supplemented with rIL-2 at 50 U/mL was added. Half the 519 
media was replaced every three days or split into new T25 tissue culture flasks (Costar, St. 520 
Louis, MO) as determined by cell confluency. After 13 days in culture, the line was screened by 521 
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tetramer staining and then cryopreserved on day 14. Sorting data are representative of a single 522 
experiment, but tetramer staining of T-cell lines was confirmed in two or more experiments.  523 
 524 
 The cell lines C58SL37 and C56SL37 were derived from PBMC from a latent 525 
tuberculosis patient and a random blood bank donor, respectively. Cells were resuspended in 50 526 
l FACS buffer and 1 uL of either mock loaded CD1b tetramer or Ac2SGL-loaded CD1b 527 
tetramer and incubated at room temperature for 20 minutes in the dark. Finally, cells were 528 
stained with anti-CD3-Fitc (clone SK7, BD, San Jose, CA), washed twice in T cell media and 529 
filtered through a cell strainer tube (Falcon, Tewksbury, MA) prior to sorting. Tetramer-positive 530 
T cells were sorted using a FACS Aria II (BD, San Jose, CA) cell sorter equipped with 407nm, 531 
488nm, and 641nm lasers. Sorted cells were expanded with the anti-CD3-based rapid expansion 532 
method seeding 1000 T cells with 40,000 irradiated EBV-transformed B cells and 200,000 533 
irradiated PBMC per well of a round bottom 96-well plate.  534 
 535 
METHOD DETAILS 536 
Isolation of sulfoglycolipids 537 
Natural Ac2SGL was purified from M. tuberculosis as previously described (Gilleron et 538 
al., 2004). Briefly, bacterial cultures (strain H37Rv) were suspended in chloroform/methanol 539 
(1:1) and filtered four times. The extract was concentrated and further partitioned by addition of 540 
water and chloroform. The chloroform was evaporated and redissolved in a minimal volume of 541 
chloroform. Acetone was added and incubated overnight at 4˚C to form a precipitate. The 542 
suspension was centrifuged at 3,000xg for 15 minutes at 4˚C. The acetone-soluble phase was 543 
fractionated on a silicic column and irrigated by various chloroform/methanol solutions (10, 20, 544 
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and 30% methanol). Natural Ac2SGL is found in the 20% methanol fraction. This fraction was 545 
further purified by reverse phase chromatography, and validated by thin layer chromatography 546 
on aluminum-backed silica gel plates (Alugram Sil G; Macherey-Nagel, Germany). Chemical 547 
synthesis of SL37 Ac2SGL is the subject of a previous manuscript (Gau et al., 2013).  548 
 549 
Synthesis of AM Ac2SGL 550 
Chemical synthesis of AM Ac2SGL consisted of a separate synthesis of hydroxyphthioceranic 551 
acid and a subsequent assembly of AM Ac2SGL. Hydroxyphthioceranic acid was synthesized by 552 
the combination of efficient asymmetric Cu-catalyzed iterative conjugated addition protocol with 553 
lithiation/borylation strategy in the later stage of synthesis (Des Mazery et al., 2005; López et al., 554 
2006; ter Horst, Feringa and Minnaard, 2007a; Casas-Arce et al., 2008; Madduri and Minnaard, 555 
2010; Geerdink, Horst, Lepore, Mori, Puzo, Anna K H Hirsch, et al., 2013; Geerdink and 556 
Minnaard, 2014; Rasappan and Aggarwal, 2014). 557 
 558 
1 .Retrosynthetic Analysis of Hydroxyphtioceranic Acid 559 
The retrosynthetic analysis outlined in Scheme 1 shows that disconnection of 3 would lead to 560 
carbamate 5 and alkyl boronate. Carbamate 5 could be constructed from building blocks 6 and 7 561 
by lithiation/borylation. Boronate 6 would be derived from 8 via Cu-catalysed iterative conjugate 562 
additions (Des Mazery et al., 2005; López et al., 2006; ter Horst, Feringa and Minnaard, 2007a, 563 
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2007b; Madduri and Minnaard, 2010) followed by lithiation/borylation, and carbamate 7 could 564 
be obtained by Cu-catalysed iterative conjugate additions followed by carbamoylation of alcohol.  565 
 566 
 567 
 568 
1.1 Synthesis of boronate 6: 569 
 The synthesis of 6 was commenced from known compound 9 (Madduri and Minnaard, 2010) 570 
which was readily obtained in 5 steps from compound 8 by Cu-catalysed iterative asymmetric 571 
conjugate addition followed by thioester reduction. Horner–Wadsworth–Emmons reaction of 9 572 
with with (OEt)2POCH2COMe gave unsaturated ketone 10 in 85% yield. Third methyl group 573 
was installed by Cu-catalyzed asymmetric conjugate addition protocol on 10 to afford 11 in 91% 574 
yield with excellent selectivity, which on Baeyer-Villiger oxidation with sodium percarbonate 575 
followed by hydrolysis afforded the alcohol in 82% yield (Wu, Harutyunyan and Minnaard, 576 
2014). Boronate 14 was achieved from alcohol in 2 steps with an overall yield of 46% by 577 
carbomolation of alcohol and lithiation/borylation of carbamate with pinacolborane, and 578 
C14H29
OH
OOH
O OTBDPSN
O
OTBDPS
PinB
6
MOMO O N
O
iPr
iPr
7
3
5
OTBDPS
EtS
O
8
Scheme 1: Retrosyntheis of hydroxyphthioceranic acid. TBDPS: tert-butyldiphenylsilyl, PinB: pinacolboronate
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homologated boronate 6 was afforded by stereoselective deprotonation of ethyl carbamate with 579 
sec. BuLi/(−)-spartein followed by treatment with boronate 13 in 62% yield. 580 
 581 
 582 
 583 
 584 
1.2 Synthesis of carbamate 7:  585 
Synthesis of ketone 15 was prepared from aldehyde 9 using Cu-catalyzed asymmetric conjugate 586 
addition protocol. Alcohol 16 was acheived from compound 15 by Baeyer-Villiger oxidation 587 
with sodium percarbonate followed by hydrolysis in 77% yield, which on protection of the 588 
hydroxyl group as MOM ether 17, followed by deprotection of TBDPS ether with TBAF and 589 
carbomoylation of formed alcohol 18 efficiently produced carbomate 7 in 76% over three steps 590 
as shown in Scheme 3. 591 
 592 
O OTBDPS PinB OTBDPS
EtS
O
OTBDPS
ref 10e
OTBDPS
O
OTBDPS
O
OTBDPS
O
HO OTBDPS
O
N
OTBDPS
PinB
8 9 10
11 12
13 14
6
Scheme 2: a) (EtO)2POCH2COMe, n-BuLi, THF, rt, 85%; b)  MeMgBr, R,S-Josiphos, CuBr
.SMe2,  t-BuOMe, -75
oC, 91%; 
c) 1. (CF3CO)2O, sodium percarbonate, DCM, rt, 2. K2CO3, MeOH, rt, 82%; d) (
iPr)2NCOCl, NEt3, toluene, 150
oC, 83%; 
e) Sec. BuLi, TMEDA, PinBH, ether, -78oC, 55%; f) EtOCb, Sec. BuLi, (-)-Spartein, ether, -78oC, 62%.
a
cb d
e f
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 593 
 594 
1.3 Synthesis of hydroxyphthioceranic acid 3:  595 
The end game for the synthesis of hydroxyphthioceranic acid depicted in Scheme 4. The 596 
coupling of two bulding blocks achieved by deprotonation of carbamate 7 with sec. 597 
BuLi/TMEDA followed by treatment with boronate 8 upon protodeborylation afforded the 598 
polydeoxypropionate 19 in 36% yield. Deprotection of MOM ether followed by carbomoylation 599 
of formed alcohol produced carbamate 20 in 70% yield over two steps. Long hydrocarbon chain 600 
was introduced by stereoselctive deprotonation of carbomate 20 with sec. BuLi/(+)-spartein 601 
followed by treatment with boronate, further oxidation of formed boronate with H2O2 afforded 602 
21 in 40% yield. Hydroxyphthioceranic acid was achieved from 21 by deprotection of silyl ether 603 
with TBAF followed by oxidation. Crude hydroxyphthioceranic acid was used for the assembly 604 
of Ac2SGL without purification. 605 
 606 
 607 
16
HO OTBDPS
MOMO O
dr > 95%
N
O
iPr
iPr
OTBDPS
O
9
ref 10e
OTBDPS
O
15
17
MOMO OTBDPS
b c
18
MOMO OH
d
7
Scheme 3: a) 1. (CF3CO)2O, sodium percarbonate, DCM, rt, 2. K2CO3, MeOH, rt, 77%; b) MOM-Cl,DIPEA, DCM, rt, 88%; c) TBAF·3H2O, 
THF, rt, 97%; d) (iPr)2NCOCl, NEt3, toluene, 150 
oC, 89%.
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 608 
 609 
2. Synthesis of Ac2SGL 2: 610 
The end game for the synthesis of Ac2SGL is depicted in Scheme 5 (Guiard et al., 2008, 2009; 611 
Leigh and Bertozzi, 2008; Sarpe and Kulkarni, 2014). Hydroxyphthioceranic acid 3 was 612 
regioselectively coupled to the trehalose core 22 by using Yamaguchi conditions, affording 23 in 613 
68% yield. The TIPS ether was removed by using a buffered TBAF solution to provide 24 in 614 
79% yield. Using a reported procedure, regioselective 2'-O-sulfation on 24 was carried out to 615 
afford 25 in 69% yield. Finally, we attempted to deprotect benzylidene acetals and TCE groups 616 
in one-step using hydrogenolysis conditions. The usual hydrogenolysis with H2/Pd(OH)2-C was 617 
given the product in low yield. Several hydrogenolysis strategies were attempted, but the 618 
combination of Pd(OH)2-C and Pd-C was afforded the Ac2SGL 2 in 71% yield. 619 
MOMO O N
O
iPr
iPr
7
OTBDPS
PinB
8
MOMO OTBDPS
BPin
5
MOMO OTBDPS
19
O OTBDPS
O
N
OTBDPS
a
b
c
20
d
C14H29
OH
C14H29 BPin
e
OH
C14H29
OH O
21 3
Scheme 4: a) Sec. BuLi, TMEDA, ether, -78 oC to 60 oC, b) 1) MeLi, ether, -78 oC, 2) Mn(OAc)3, TBC, DCE, 60 
oC, c) 1) ZnBr2, 
nPrSH, DCM, rt, d) 
Sec. BuLi, (+)-Spartein, ether, -60 oC to 60 oC, e) 1) TBAF, THF, rt, 2) TEMPO, NaClO2, NaOCl, Phosphate buffer, CH3CN
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Scheme 5: a) 2,4,6-trichlorobenzoylchloride, Et3N, DMAP, toluene, 68%; b) TBAF (1M in THF, PH=6.5), THF, 
40 C, 79%; c) 1,2-Dimethylimidazole, THF, rt, 69%; d) NH4HCO2, Pd(OH)2/C, Pd/C, MeOH/CH2Cl2, 71%.
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All reactions were performed under nitrogen atmosphere using dry glassware and dry solvents. 622 
MTBE, Et2O, THF, toluene and DCM were taken from an MBraun solvent purification system 623 
(SPS-800). TMEDA was freshly distilled from CaH2 and stored under argon atmosphere. (+)-624 
Sparteine was purchased from BOC-Science and stored in a glovebox. (˗)-Sparteine was 625 
liberated from the commercially available sulfate salt (Nikolic and Beak, 1997). (R,S)-626 
Josiphos.EtOH was purchased from Solvias and stored under argon atmosphere. TLC analysis: 627 
Merck silica gel 60/Kieselguhr F254, 0.25 mm. Compounds were visualized using either 628 
anisaldehyde stain or potassium permanganate stain. Flash chromatography: SiliCycle silica gel 629 
type SiliaFlash P60 (230-400 mesh). 630 
 631 
Chemical characterization of AM Ac2SGL and its synthetic intermediates 632 
 633 
1H- and 13C-NMR spectra were recorded on a Varian 400-MR (400, 100.6 MHz, respectively). 634 
High resolution mass spectra were recorded on a Thermo Scientific LTQ Orbitrap XL. 635 
Enantiomeric excess was determined by HPLC (Chiracel OB, 250*4.6 mm, 10 μm) using a PDA 636 
detector (Shimadzu).  637 
 638 
 639 
1. (6S,8S,E)-9-((tert-butyldiphenylsilyl)oxy)-6,8-dimethylnon-3-en-2-one (10): 640 
 641 
 642 
To a solution of (EtO)2POCH2COMe (3.53 g, 18.2 mmol, 1.3 eq) dissolved in THF (93 mL) 643 
under nitrogen and cooled to 0 °C, n-butyllithium (10.5 mL, 16.8 mmol, 1.2 eq, 1.6 M in hexane) 644 
OTBDPS
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was added slowly at 0 °C. The reaction mixture was stirred for 10 min at rt. Then aldehyde 9 645 
(5.35 g, 14.0 mmol, 1.0 eq), dissolved in 3 mL THF was slowly added and the reaction mixture 646 
stirred at rt for 10 h. The reaction mixture was washed with distilled water and extracted with 647 
diethyl ether. The combined organic phases were dried over MgSO4 and concentrated under 648 
reduced pressure to yield crude 10. Purification by flash chromatography (8% ether in pentane) 649 
afforded α,β-unsaturated ketone 10 as a colorless oil (5.04 g, 85% yield). [α]D22 = –8.5o (c = 1.3, 650 
CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.69 – 7.67 (m, 4H), 7.45 – 7.37 (m, 6H), 6.76 (dt, J = 651 
15.3, 7.4 Hz, 1H), 6.07 (d, J = 15.9 Hz, 1H), 3.52 (dd, J = 10.0, 5.2 Hz, 1H), 3.46 (dd, J = 9.6, 652 
6.4 Hz 1H), 2.26 – 2.19 (m, 1H), 2.23 (s, 3H), 2.03 – 1.95 (m, 1H), 1.80 – 1.65 (m, 2H), 1.48 – 653 
1.41 (m, 1H), 1.06 (s, 9H), 1.03 – 0.89 (m, 1H), 0.96 (d, J = 6.7 Hz, 3H), 0.88 (d, J = 6.6 Hz, 654 
3H); 13C NMR (101 MHz, CDCl3) δ 198.52, 147.22, 135.61, 135.60, 133.94, 132.56, 129.56, 655 
127.61, 68.66, 40.75, 39.80, 33.15, 30.04, 26.90, 26.83, 20.21, 19.32, 17.63. HRMS, calcd for 656 
C27H38O2SiNa (M+Na
+) 445.253, found 445.253. 657 
 658 
 659 
2. (4R,6S,8S)-9-((tert-butyldiphenylsilyl)oxy)-4,6,8-trimethylnonan-2-one (11): 660 
 661 
 662 
(R,SFe)-Josiphos•CuBr complex (88.0 mg, 0.112 mmol, 1 mol%) was dissolved in t-BuOMe (60 663 
mL) under nitrogen. The mixture was cooled to –80 °C and methylmagnesium bromide (4.46 mL 664 
13.4 mmol, 3 M solution in diethyl ether) was added dropwise over 10 min. After stirring for 10 665 
min, a solution of enone 10 (4.73 g, 11.2 mmol) in t-BuOMe (20 mL) was added via syringe 666 
pump over 1.5 h. The reaction mixture was stirred at –80 °C for 18 h, then quenched by the 667 
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addition of MeOH and allowed to warm to room temperature. Saturated aqueous NH4Cl was 668 
added, and after phase separation and extraction of the aqueous phase with diethyl ether, the 669 
combined organic phases were dried over MgSO4, concentrated under reduced pressure and 670 
purified by column chromatography (5% ether in pentane) to afford 11 as a colourless oil (4.48 671 
g, 91% yield). [α]D22 = –7.4o (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.68-7.65 (m, 4H), 672 
7.44-7.35 (m, 6H), 3.51 (dd, J = 10.0, 5.1 Hz, 1H), 3.42 (dd, J = 9.8, 6.5 Hz, 1H), 2.37 (app q, J 673 
= 8.4 Hz, 1H), 2.10 (app t, J = 8.4 Hz, 1H), 2.09 (s, 3H), 1.76-1.68 (m, 1H), 1.51-1.42 (m, 1H), 674 
1.40 – 1.33 (m, 1H), 1.21 – 1.12 (m, 2H), 1.07 (s, 9H), 0.98– 0.88 (m, 2H), 0.94 (d, J = 6.4 Hz, 675 
3H), 0.85 (d, J = 6.4 Hz, 3H), 0.82 (d, J = 6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 208.66, 676 
135.50, 135.48, 133.90, 133.87, 129.40, 129.39, 127.47, 127.46, 68.62, 50.70, 44.94, 41.12, 677 
33.02, 30.26, 27.58, 26.81, 26.65, 20.64, 20.52, 19.20, 18.00. HRMS, calcd for C28H42O2SiNa 678 
(M+Na+) 461.285, found 461.284. 679 
 680 
 681 
3. (2R,4S,6S)-7-((tert-butyldiphenylsilyl)oxy)-2,4,6-trimethylheptan-1-ol (12): 682 
 683 
 684 
To a mixture of compound 11 (3.27 g, 7.5 mmol) and sodium percarbonate (10 eq, 11.8 g) in 685 
DCM (75 mL), trifluoroacetic anhydride (5 eq, 5.25 mL) was added. The reaction was stirred at 686 
room temperature for 2 days and filtered through a Celite pad. The filtrate was neutralized with 687 
sat. NaHCO3(aq) and the aqueous layer was back-extracted with Et2O. The organic phases were 688 
dried over MgSO4, concentrated and purified by column chromatography (10% ether in pentane) 689 
to afford the acetate as colorless oil (2.92 g, 86% yield). The product acetate (1.66 g, 3.8 mmol) 690 
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was dissolved in methanol (5 mL) and potassium carbonate (1.3 eq, 0.67 g) was added. The 691 
reaction was stirred at room temperature for 3 h, after which it was diluted with water and 692 
extracted with Et2O. The combined organic phases were dried over MgSO4, filtered and 693 
concentrated. The product was purified by flash chromatography (50% ether in pentane) to give 694 
compound 12 as colorless oil (1.49 g, 95%). [α]D22 = –3.4o (c = 1.0, CHCl3). 1H NMR (400 MHz, 695 
CDCl3) δ 7.83 – 7.57 (m, 4H), 7.49 – 7.30 (m, 6H), 3.52 (dd, J = 5.0, 2.6 Hz, 1H), 3.49 (dd, J = 696 
5.0, 3.2 Hz, 1H), 3.41 (dd, J = 9.8, 6.5 Hz, 1H), 3.33 (dd, J = 10.4, 6.8 Hz, 1H), 1.79 – 1.65 (m, 697 
2H), 1.58 – 1.47 (m, 1H), 1.37 (m, 1H), 1.31 – 1.20 (m, 1H), 1.05 (s, 9H), 0.93 (d, J = 6.7 Hz, 698 
3H), 0.91 – 0.82 (m, 2H), 0.89 (d, J = 6.7 Hz, 3H), 0.84 (d, J = 6.5 Hz, 3H); 13C NMR (101 699 
MHz, CDCl3) δ 135.63, 135.60, 134.07, 134.04, 129.46, 127.53, 68.72, 68.16, 41.24, 41.21, 700 
33.19, 33.06, 27.75, 26.88, 20.97, 19.30, 18.04, 17.62. HRMS, calcd for C26H40O2SiNa (M+Na
+) 701 
435.269, found 435.268. 702 
 703 
4. (2R,4S,6S)-7-((tert-butyldiphenylsilyl)oxy)-2,4,6-trimethylheptyl diisopropylcarbamate (13):  704 
 705 
 706 
Compound 12 (1.20 g, 2.88 mmol) was dissolved in anhydrous toluene (3.5 mL) and diisopropyl 707 
carbamoyl chloride (943 mg, 5.76 mmol, 2.0 eq) and dry triethylamine (1.0 mL, 7.2 mmol, 2.5 708 
eq) were added. The reaction mixture was heated at 150 °C in a microwave reactor for 2 h. The 709 
mixture was cooled to room temperature, washed with HCl (2 M aq.), dried over MgSO4, filtered 710 
and concentrated. The product was purified by flash chromatography (10% ether in pentane) to 711 
give compound 13 as colorless oil (1.29 g, 83%). [α]D22 = −6.7o (c = 1.0, CHCl3). 1H NMR (400 712 
MHz, CDCl3) δ 7.72-7.68 (m, 4H), 7.45-7.37 (m, 6H), 4.03 (dd, J = 10.5, 4.9 Hz, 1H), 3.87 (dd, 713 
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J = 10.6, 6.7 Hz, 1H), 3.55 (dd, J = 9.8, 5.2 Hz, 1H), 3.45 (dd, J = 9.8, 6.5 Hz, 1H), 2.00 – 1.87 714 
(m, 1H), 1.82 – 1.71 (m, 1H), 1.65 – 1.52 (m, 1H), 1.46 – 1.30 (m, 2H), 1.26 – 1.21 (m, 2H), 715 
1.24 (s, 6H), 1.23 (s, 6H), 1.10 (s, 9H), 0.98 (d, J = 7.2 Hz, 3H), 0.96 (d, J = 7.2 Hz, 3H), 0.94 – 716 
0.90 (m, 2H), 0.98 (d, J = 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 155.90, 135.64, 135.61, 717 
134.04, 134.01, 129.51, 127.58, 69.41, 68.83, 45.06, 41.46, 41.31, 33.21, 30.35, 27.66, 26.93, 718 
20.98, 19.32, 18.51, 17.95. HRMS, calcd for C33H53NO3SiNa (M+Na
+) 562.367, found 562.367. 719 
 720 
5. tert-butyldiphenyl(((2S,4S,6S)-2,4,6-trimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-721 
yl)heptyl)oxy)silane (14): 722 
 723 
 724 
sBuLi (1.7 mL, solution in cyclohexane, 1.4 M, 1.2 eq) was added dropwise to a solution of 725 
carbamate 13 (1.09 g, 2.0 mmol, 1.0 eq) and TMEDA (0.39 mL, 2.6 mmol, 1.3 eq.) in anhydrous 726 
Et2O (9 mL) at -78 °C. The reaction mixture was stirred for 5 h at -78 °C and then a solution of 727 
pinacol borane (0.58 mL, 4.0 mmol, 2.0 eq) in anhydrous Et2O (1 mL) was added slowly and the 728 
mixture was stirred for 1 h at -78 °C. The cooling bath was removed, the reaction mixture was 729 
warmed to 40 °C and kept at this temperature for 12 h. The reaction mixture was subsequently 730 
cooled to 0 °C, diluted with KH2PO4 (1 M aq., 40 mL) and stirred for an additional 10 min. The 731 
phases were separated, and the aqueous phase was extracted with ether. The combined organic 732 
layers were dried over anhydrous MgSO4, filtered, concentrated and purified by column 733 
chromatography (2% ether in pentane) to give boronate 14 (0.57 g, 55%) as colorless oil. [α]D22 = 734 
−4.6o (c = 1.4, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.91 – 7.56 (m, 4H), 7.52 – 7.28 (m, 6H), 735 
3.52 (dd, J = 9.8, 5.1 Hz, 1H), 3.39 (dd, J = 9.8, 6.8 Hz, 1H), 1.76 (m, 2H), 1.55 – 1.45 (m, 1H), 736 
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1.36–1.30 (m, 1H), 1.25 (s, 12H), 1.23 – 1.12 (m, 2H), 1.06 (s, 9H), 0.93 (d, J = 6.8 Hz, 3H), 737 
0.91 – 0.85 (m, 2H), 0.89 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 6.8 Hz, 3H), 0.55 (dd, J = 15.3, 8.6 738 
Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 135.62, 135.60, 134.13, 134.11, 129.41, 129.40, 127.51, 739 
82.74, 68.98, 47.49, 41.47, 34.11, 33.11, 27.71, 26.88, 26.79, 24.91, 24.74, 23.27, 22.32, 20.80, 740 
19.29, 17.86, 14.05. HRMS, calcd for C32H51BO3SiNa (M+Na
+) 545.359, found 545.359. 741 
 742 
 743 
6. tert-butyldiphenyl(((2S,4S,6S,8R)-2,4,6-trimethyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-744 
yl)nonyl)oxy)silane (6): 745 
 746 
 747 
sBuLi (solution in cyclohexane, 1.4 M, 0.93 mL, 1.3 eq) was added dropwise to a solution of 748 
ethyl carbamate (0.24 g, 1.4 mmol, 1.4 eq) and (−)-sparteine (0.33 g, 1.4 mmol, 1.4 eq) in 749 
anhydrous Et2O (5 mL) at -78 °C. The reaction mixture was stirred for 5 h at −78 °C and then a 750 
solution of boronate 14 (0.52 g, 1.0 mmol, 1.0 eq) in anhydrous Et2O (2 mL) was added. The 751 
reaction mixture was stirred for 1 h at −78 °C. The cooling bath was removed and the reaction 752 
mixture was warmed to 50 °C and kept at this temperature for 12 h. The reaction mixture was 753 
cooled to 0 °C and diluted with KH2PO4 (1 M aq., 2 mL) and stirred for an additional10 min. 754 
The phases were separated, and the aqueous phase was extracted with ether. The combined 755 
organic layers were dried over anhydrous MgSO4, filtered, concentrated and purified by column 756 
chromatography (1% followed by 2% ether in pentane) to give pinacol boronate 6 (0.344 g, 757 
62%) as colorless, viscous oil. [α]D22 = −5.7o (c = 1.3, CHCl3). 1H NMR (400 MHz, CDCl3) δ 758 
7.72-7.58 (m, 4H), 7.48-7.39 (m, 6H), 3.54 (dd, J = 10.0, 5.1 Hz, 1H), 3.42 (dd, J = 9.5, 6.7 Hz, 759 
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1H), 1.80 – 1.72 (m, 1H), 1.65 – 1.48 (m, 2H), 1.41 – 1.30 (m, 1H), 1.28 – 1.21 (m, 2H), 1.24 (s, 760 
12H), 1.15 – 1.10 (m, 2H), 1.08 (s, 9H), 0.98 (d, J = 7.2 Hz, 3H), 0.95 (d, J = 7.2 Hz, 3H), 0.88 – 761 
0.82 (m, 8H); 13C NMR (101 MHz, CDCl3) δ 135.63, 135.62, 134.13, 134.11, 129.45, 129.43, 762 
127.54, 82.68, 68.87, 45.75, 41.42, 40.75, 33.15, 29.56, 27.45, 26.91, 24.78, 24.74, 20.77, 19.32, 763 
18.05, 16.48. HRMS, calcd for C34H55BO3SiNa (M+Na
+) 573.391, found 573.390. 764 
 765 
 766 
7. (2R,4R,6S,8S)-9-((tert-butyldiphenylsilyl)oxy)-2,4,6,8-tetramethylnonan-1-ol (16): 767 
 768 
 769 
 770 
To a mixture of compound 15 (4.85 g, 10 mmol) and sodium percarbonate (16 eq, 25 g) in DCM 771 
(170 mL), trifluoroacetic anhydride (4 eq, 5.5 mL) was added. The reaction was stirred at room 772 
temperature for 16 h, and then a fresh portion of sodium percarbonate (8 eq, 12.5 g) and 773 
trifluoroacetic anhydride (2 eq, 2.7 ml) was added. The reaction was stirred for a subsequent 2 774 
days and then filtered through a Celite pad. The filtrate was neutralized with sat. solution of 775 
NaHCO3(aq) and the aqueous layer was back-extracted with Et2O (3x). The organic phases were 776 
dried over MgSO4, filtered and concentrated. The residue was dissolved in methanol (10 mL) 777 
and potassium carbonate (1.1 eq, 1.5 g) was added. The reaction was stirred at room temperature 778 
for 3 h, after which it was diluted with water and extracted with Et2O. The combined organic 779 
phases were dried over MgSO4, filtered and concentrated. The product was purified by flash 780 
chromatography (25% ether in pentane) to give compound 16 as colorless oil (3.5 g, 77%). [α]D22 781 
= −2.5o (c = 0.8, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.79 – 7.58 (m, 4H), 7.49 – 7.31 (m, 782 
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6H), 3.55 – 3.49 (m, 2H), 3.42 (dd, J = 9.8, 6.4 Hz, 1H), 3.35 (dd, J = 10.5, 6.9 Hz, 1H), 1.72 (m, 783 
2H), 1.61 – 1.45 (m, 3H), 1.38 (m, 1H), 1.32 – 1.13 (m, 3H), 1.05 (s, 9H), 0.94 (d, J = 6.8 Hz, 784 
3H), 0.92 (d, J = 6.8 Hz, 3H), 0.90 – 0.86 (m, 2H), 0.84 (d, J = 6.4 Hz, 3H), 0.81 (d, J = 6.4 Hz, 785 
3H); 13C NMR (101 MHz, CDCl3) δ 135.62, 135.60, 134.10, 129.45, 129.44, 127.53, 127.52, 786 
68.66, 68.10, 45.55, 41.11, 40.94, 33.18, 33.07, 27.65, 27.56, 26.88, 21.12, 21.00, 19.31, 18.21, 787 
17.71. HRMS, calcd for C29H46O2SiNa (M+Na
+) 477.316, found 477.315. 788 
 789 
 790 
8. (6R,8R,10S,12S)-6,8,10,12,16,16-hexamethyl-15,15-diphenyl-2,4,14-trioxa-15-791 
silaheptadecane (17): 792 
 793 
 794 
 795 
To a solution of compound 16 (1.34 g, 2.95 mmol) in anhydrous DCM (15 mL) was added N,N-796 
diisopropylethylamine (2.0 eq, 1 mL) and chloromethyl methyl ether (1.5 eq, 0.36 mL), and the 797 
reaction mixture was stirred at room temperature overnight. The mixture was diluted with Et2O, 798 
washed with HCl (10% aq., 2x) and brine, dried over MgSO4, filtered and concentrated. The 799 
product was purified by flash chromatography (2% Et2O in pentane) to give compound 17 as 800 
colorless oil (1.3 g, 88%). [α]D22 = −7.5o (c = 1.3, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.84 – 801 
7.55 (m, 4H), 7.50 – 7.29 (m, 6H), 4.60, 4.61 (AB q, J = 6.4 Hz, 2H), 3.51 (dd, J = 9.8, 5.0 Hz, 802 
1H), 3.44 – 3.38 (m, 2H), 3.35 (s, 3H), 3.24 (dd, J = 9.3, 7.1 Hz, 1H), 1.88 – 1.66 (m, 2H), 1.54 803 
(m, 2H), 1.34 (m, 2H), 1.24 – 1.12 (m, 2H), 1.05 (s, 9H), 0.94 (d, J = 6.8 Hz, 6H), 0.92 – 0.85 804 
(m, 2H), 0.84 (d, J = 6.4 Hz, 3H), 0.80 (d, J = 6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 805 
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135.62, 135.60, 134.09, 129.45, 129.43, 127.53, 127.52, 96.57, 73.04, 68.68, 55.05, 45.56, 41.35, 806 
41.12, 33.16, 30.82, 27.59, 27.50, 26.88, 21.04, 20.95, 19.30, 18.39, 18.18. HRMS, calcd for 807 
C31H50O3SiNa (M+Na
+) 521.342, found 521.342. 808 
 809 
 810 
9. (2S,4S,6R,8R)-9-(methoxymethoxy)-2,4,6,8-tetramethylnonan-1-ol (18): 811 
 812 
 813 
 814 
To a solution of 17 (3.28 g, 6.57 mmol) in anhydrous THF (40 mL) was added TBAF·3H2O (1.5 815 
eq, 3.1 g). The reaction mixture was stirred at room temperature overnight and then diluted with 816 
NaHCO3 (sat. aq.). The aqueous phase was extracted with diethyl ether (3x). The combined 817 
organic phases were dried over MgSO4, filtered and concentrated. The product was purified by 818 
flash chromatography (15% to 40% Et2O in pentane) to give compound 18 as colorless oil (1.66 819 
g, 97%). [α]D22 = −11.1o (c = 1.1, CHCl3). 1H NMR (400 MHz, CDCl3) δ 4.60, 4.61 (AB q, J = 820 
6.4 Hz, 2H), 3.54 (dd, J = 10.5, 4.9 Hz, 1H), 3.44 – 3.34 (m, 2H), 3.36 (s, 3H), 3.26 (dd, J = 9.3, 821 
7.0 Hz, 1H), 1.77 (m, 2H), 1.64 – 1.53 (m, 2H), 1.33 (m, 2H), 1.20 (m, 2H), 0.94 (d, J = 6.4 Hz, 822 
3H), 0.93 (d, J = 6.8 Hz, 3H), 0.92 – 0.89 (m, 2H), 0.87 (d, J = 6.4 Hz, 6H); 13C NMR (101 823 
MHz, CDCl3) δ 96.58, 73.01, 68.08, 55.07, 45.40, 41.35, 40.98, 33.08, 30.86, 27.57, 21.03, 824 
20.99, 18.38, 17.68. HRMS, calcd for C15H32O3Na (M+Na
+) 283.225, found 283.224. 825 
 826 
 827 
10. (2S,4S,6R,8R)-9-(methoxymethoxy)-2,4,6,8-tetramethylnonyl diisopropylcarbamate (19): 828 
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 829 
 830 
 831 
Compound 18 (590 mg, 2.27 mmol) was dissolved in anhydrous toluene (20 mL) and diisopropyl 832 
carbamoyl chloride (2 eq, 750 mg) and dry triethylamine (2.5 eq, 0.80 mL) were added. The 833 
reaction mixture was heated at 150 oC in a microwave reactor for 2 h. The mixture was cooled to 834 
room temperature, washed with HCl (2 M aq.), dried over MgSO4, filtered and concentrated. The 835 
product was purified by flash chromatography (10% Et2O in pentane) to give compound 19 as 836 
colorless oil (781 mg, 89%). [α]D22 = +2.0o (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 4.60, 837 
4.61 (AB q, J = 6.4 Hz, 2H), 4.00 (dd, J = 10.5, 4.7 Hz, 1H), 3.82 (dd, J = 10.5, 6.8 Hz, 1H), 838 
3.39 (dd, J = 9.3, 5.0 Hz, 1H), 3.34 (s, 3H), 3.23 (dd, J = 9.3, 7.0 Hz, 1H), 1.95 – 1.75 (m, 2H), 839 
1.67 – 1.49 (m, 2H), 1.33 (m, 2H), 1.21 (s, 6H), 1.19 (s, 6H), 1.21 – 1.12 (m, 2H), 0.96 (d, J = 840 
6.8 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H), 0.94 – 0.87 (m, 2H), 0.86 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 841 
6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 155.95, 96.55, 73.00, 69.28, 55.03, 45.52, 41.36, 842 
41.27, 30.79, 30.25, 27.43, 27.40, 20.91, 20.76, 18.60, 18.31. HRMS, calcd for C22H45NO4Na 843 
(M+Na+) 410.324, found 410.324. 844 
 845 
 846 
11. (6R,8R,10S,12S,14R,16R,18S,20S)-6,8,10,12,14,16,18,20,24,24-decamethyl-23,23-diphenyl-847 
13-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,4,22-trioxa-23-silapentacosane (5) ): 848 
 849 
 850 
MOMO O N
O
iPr
iPr
MOMO OTBDPS
BPin
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 44 
sBuLi (solution in cyclohexane, 1.4 M, 0.93 mL, 1.3 eq.) was added dropwise to a solution of 851 
carbamate 7 (0.54 g, 1.4 mmol, 1.4 eq) and TMEDA (0.21 mL, 1.4 mmol, 1.4 eq) in anhydrous 852 
Et2O (5 mL) at -78 °C. The reaction mixture was stirred for 5 h at −78 °C and then a solution of 853 
boronate 6 (0.55 g, 1.0 mmol, 1.0 eq) in anhydrous Et2O (2 mL) was added slowly and the 854 
mixture was stirred for 1 h at −78 °C. The cooling bath was removed and the reaction mixture 855 
was warmed to 40 °C and kept at this temperature for 12 h. The reaction mixture was cooled to 0 856 
°C and diluted with KH2PO4 (1 M aq., 2 mL) and stirred for an additional10 min. The phases 857 
were separated, and the aqueous phase was extracted with ether. The combined organic layers 858 
were dried over anhydrous MgSO4, filtered, concentrated and purified by column 859 
chromatography (15% ether in pentane) to give boronate 5 as a mixture of isomers  (0.53 g, 860 
67%), as a colorless liquid. [α]D22 = −3.0o (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.68-861 
7.66 (m, 4H), 7.45 – 7.33 (m, 6H), 4.62, 4.61 (AB q, J = 6.4 Hz, 2H), 3.53 (dd, J = 9.8, 4.9 Hz, 862 
1H), 3.47 – 3.38 (m, 2H), 3.36 (s, 3H), 3.25 (dd, J = 9.3, 7.1 Hz, 1H), 1.94 – 1.70 (m, 4H), 1.67–863 
1.50 (m, 4H), 1.45 – 1.27 (m, 4H), 1.28 – 1.14 (m, 2H), 1.23 (s, 12H), 1.05 (s, 9H), 0.95 (d, J = 864 
6.4 Hz, 3H), 0.94 (d, J = 6.4 Hz, 3H), 0.92 – 0.72 (m, 25H); 13C NMR (101 MHz, CDCl3) δ 865 
135.62, 135.60, 134.13, 134.11, 129.42, 129.41, 127.52, 127.51, 96.57, 82.65, 73.02, 68.68, 866 
55.04, 45.49, 45.45, 44.68, 41.24, 40.88, 33.25, 30.89, 28.74, 28.72, 27.64, 27.57, 27.32, 26.89, 867 
25.05, 21.45, 21.35, 21.13, 21.06, 19.61, 19.59, 19.31, 18.49, 18.25; HRMS, calcd for 868 
C49H89BO5SiN (M+NH4
+) 810.656, found 810.661. 869 
 870 
 871 
12. (6R,8R,10R,12R,14S,16S,18S,20S)-6,8,10,12,14,16,18,20,24,24-decamethyl-23,23-diphenyl-872 
2,4,22-trioxa-23-silapentacosane (19): 873 
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 874 
 875 
 876 
MeLi (solution in hexane, 1.6 M, 0.16 mL, 2.0 eq) was added dropwise to a solution of boronate 877 
5 (100 mg, 0.126 mmol, 1.0 eq) in anhydrous ether (5 mL) at −78 °C. The reaction mixture was 878 
stirred for 1 h at −78 °C before being warmed to room temperature. Solvents were subsequently 879 
removed under reduced pressure in situ. Then the septum was removed and under a positive 880 
pressure of argon, Mn(OAc)3·2H2O (33.8 mg, 0.126 mmol, 1.0 eq) and 4-tertbutyl catechol 881 
(104.7 mg, 0.63 mmol, 5.0 eq.) were added to the reaction vessel. The septum was placed back 882 
and anhydrous DCE (5 mL) was added to the reaction mixture. The resulting brown solution was 883 
heated at 80 °C for 12 h. The reaction mixture was subsequently cooled to room temperature, 884 
filtered through a plug of Celite, washed with Et2O (3 × 40 mL) and the solvent was removed 885 
under reduced pressure. The crude product was purified by flash column chromatography (SiO2, 886 
5% ether in pentane) to give the silyl ether 19 (45.5 mg, 54%) as colorless oil. [α]D22 = −5.8o (c = 887 
0.5, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.80 – 7.53 (m, 4H), 7.51 – 7.27 (m, 6H), 4.63 (s, 888 
2H), 3.52 (dd, J = 9.8, 5.0 Hz, 1H), 3.42 (m, 2H), 3.36 (s, 3H), 3.26 (dd, J = 9.3, 7.1 Hz, 1H), 889 
1.91 – 1.78 (m, 2H), 1.64-1.48 (m, 6H), 1.42-1.32 (m, 2H), 1.26-1.15 (m, 6H), 1.06 (s, 9H), 0.95 890 
(d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H), 0.89 – 0.78 (m, 24H); 13C NMR (101 MHz, CDCl3) 891 
δ 135.64, 135.62, 134.12, 134.08, 129.45, 127.54, 96.59, 73.04, 68.70, 55.06, 45.51, 45.36, 892 
45.32, 45.30, 41.36, 41.11, 33.22, 30.88, 27.73, 27.65, 27.56, 26.91, 21.49, 21.47, 21.39, 21.32, 893 
21.17, 21.14, 19.32, 18.43, 18.23; HRMS of 19 could not be obtained due to suppressed 894 
ionization. 895 
 896 
MOMO OTBDPS
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 46 
 897 
13. (2R,4R,6R,8R,10S,12S,14S,16S)-17-((tert-butyldiphenylsilyl)oxy)-2,4,6,8,10,12,14,16-898 
octamethylheptadecyl diisopropylcarbamate (20): 899 
 900 
 901 
To a stirred solution of 19 (173.6 mg, 0.26 mmol) and n-PrSH (47 μL, 0.51 mmol) in CH2Cl2 (20 902 
mL) was added ZnBr2 (58.0 mg, 0.26 mmol) at 0 °C. After stirring for 10 min at room 903 
temperature, the reaction mixture was diluted with CH2Cl2 (100 mL). The reaction was quenched 904 
with satd. NaHCO3(aq) at 0 °C, and the mixture was filtered through Celite. The organic phase 905 
was separated and the aqueous phase was further extracted with CH2Cl2. The combined organic 906 
layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product 907 
was dissolved in anhyd. toluene (3 mL) and diisopropyl carbamoyl chloride (1.1 eq, 46 mg) and 908 
dry triethylamine (2.5 eq, 7 μL) were added. The reaction mixture was heated at 150 oC in a 909 
microwave reactor for 2 h. The mixture was cooled to room temperature, washed with HCl (2 M 910 
aq.), dried over MgSO4, filtered and concentrated. The product was purified by flash 911 
chromatography (10% Et2O in pentane) to give compound 20 as colorless oil (135 mg, 70%). 912 
[α]D22 = −6.6o (c = 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.87 – 7.52 (m, 4H), 7.39 (m, 913 
6H), 4.16-3.74 (br. s, 2H), 4.03 (dd, J = 10.6, 4.7 Hz, 1H), 3.86 (dd, J = 10.6, 6.8 Hz, 1H), 3.53 914 
(dd, J = 9.6, 5.0 Hz, 1H), 3.42 (dd, J = 9.8, 6.3 Hz, 1H), 2.01 – 1.84 (m, 2H), 1.77-1.72 (m, 2H), 915 
1.65-1.51 (m, 6H), 1.47 – 1.35 (m, 2H), 1.33-1.27 (m, 4H), 1.23 (s, 6H), 1.21 (s, 6H), 1.07 (s, 916 
9H), 0.99 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.91 – 0.78 (m, 24H); 13C NMR (101 917 
MHz, CDCl3) δ 155.96, 135.63, 135.61, 134.10, 134.07, 129.45, 129.44, 127.54, 127.53, 69.30, 918 
68.69, 45.50, 45.45, 45.31, 45.26, 41.23, 41.10, 33.22, 30.32, 27.73, 27.60, 27.57, 27.54, 27.49, 919 
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26.91, 21.47, 21.42, 21.39, 21.25, 21.18, 21.00, 19.31, 18.67, 18.24, 15.28. HRMS, calcd for 920 
C48H84NO3Si (M+H
+) 750.622, found 750.621 (Sohn et al., 2005). 921 
 922 
 923 
14. (16R,17R,19R,21R,23R,25S,27S,29S,31S)-32-((tert-butyldiphenylsilyl)oxy)-924 
17,19,21,23,25,27,29,31-octamethyldotriacontan-16-ol (21): 925 
 926 
 927 
 928 
sBuLi (solution in cyclohexane, 1.4 M, 0.12 mL, 1.3 eq) was added dropwise to a solution of 929 
carbamate 20 (0.115 g, 0.153 mmol, 1.0 eq) and (+)-spartein (50.2 mg, 0.214 mmol, 1.4 eq) in 930 
anhydrous TBME (3 mL) at −60 °C. The reaction mixture was stirred for 5 h at −60 °C and then 931 
a solution of boronate (0.104 g, 0.31 mmol, 2.0 eq) in anhydrous TBME (2 mL) was added 932 
slowly and the mixture was stirred for 1 h at −60 °C. The cooling bath was removed and the 933 
reaction mixture was warmed to 70 °C and kept at this temperature for 16 h. The reaction 934 
mixture was cooled to 0 °C and quenched with 2 mL of H2O2 (1 mL of H2O2 in 4 mL of 1 M 935 
NaOH) and stirred for 30 min at rt. The reaction mixture was washed with ether and the 936 
combined organic layers were dried over anhydrous MgSO4, filtered, concentrated and purified 937 
by column chromatography (6% ether in pentane) to give alcohol 21 (51.1 mg, 40%) as colorless 938 
liquid. [α]D22 = +8.7o (c = 0.2, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.91 – 7.56 (m, 4H), 7.40 939 
(m, 6H), 3.62 – 3.49 (m, 2H), 3.43 (ddd, J = 9.7, 6.4, 2.5 Hz, 1H), 1.75 (dt, J = 11.9, 4.1 Hz, 2H), 940 
1.66 – 1.50 (m, 8H), 1.43 (m, 6H), 1.30-1.21 (m, 29H), 1.07 (s, 9H), 0.95 (d, J = 6.8 Hz, 3H), 941 
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0.96 – 0.73 (m, 30H). 13C NMR (101 MHz, CDCl3) δ 135.64, 135.61, 134.12, 134.09, 129.44, 942 
127.53, 74.31, 68.70, 45.50, 45.30, 45.27, 41.14, 41.10, 35.09, 34.91, 33.22, 31.93, 30.33, 29.78, 943 
29.70, 29.66, 29.64, 29.37, 27.72, 27.68, 27.65, 27.62, 27.58, 27.55, 26.90, 26.38, 22.70, 21.50, 944 
21.48, 21.45, 21.38, 21.26, 21.16, 19.31, 18.23, 14.13, 14.02. HRMS, calcd for C56H100NaO2Si 945 
(M+Na+) 855.739, found 855.738. 946 
 947 
Deprotection of 21 followed by oxidation to hydroxyphthioceranic acid 3 was carried out 948 
according to our previous work (Geerdink, Horst, Lepore, Mori, Puzo, Anna K H Hirsch, et al., 949 
2013). 950 
 951 
15. (2R,4aR,6R,7R,8S,8aR)-7-(palmitoyloxy)-2-phenyl-6-(((5aR,6R,7aR,10R,11aR,11bS)-952 
2,2,4,4-tetraisopropyl-10-phenylhexahydro-[1,3]dioxino[4',5':5,6]pyrano[3,4-953 
f][1,3,5,2,4]trioxadisilepin-6-yl)oxy)hexahydropyrano[3,2-d][1,3]dioxin-8-yl 954 
(2S,4S,6S,8S,10R,12R,14R,16R,17R)-17-hydroxy-2,4,6,8,10,12,14,16-955 
octamethyldotriacontanoate (23): 956 
 957 
 958 
To hydroxyphthioceranic acid 3 (97.5 mg, 0.16 mmol) in benzene (5.0 mL) was added Et3N (2.1 959 
eq, 48 μL, 0.34 mmol) and 2,4,6-trichlorobenzoyl chloride (1.05 eq, 26 μL, 0.17 mmol). After 1 960 
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h, protected trehalose (4.0 eq, 639.6 mg, 0.64 mmol) in 5.0 mL of benzene and DMAP (1.1 eq, 961 
21.5 mg, 0.18 mmol) were added. The reaction was stirred for 48 h and quenched with an aq. 962 
saturated solution of NaHCO3. The layers were separated and the aqueous layer was extracted 963 
with EtOAc. The combined organic layers were dried over MgSO4 and all volatiles were 964 
evaporated. The crude product was purified using flash chromatography (gradient elution, 15, 17, 965 
19% ether in pentane) to give pure 23 as a colorless oil (174.1 mg, 68%). [α]D22 = +27.4o (c = 966 
1.0, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.44 (m, 2H), 7.41 – 7.36 (m, 2H), 7.31 (m, 6H), 967 
5.65 (t, J = 9.8 Hz, 1H), 5.52 (s, 1H), 5.45 (s, 1H), 5.36 (d, J = 3.9 Hz, 1H), 5.11 (d, J = 4.0 Hz, 968 
1H), 5.01 (dd, J = 10.0, 3.6 Hz, 1H), 4.29 (m, 1H), 4.24 – 4.16 (m, 2H), 4.12 (dd, J = 10.0, 4.7 969 
Hz, 1H), 3.89 (dd, J = 8.5, 4.1 Hz, 1H), 3.85 – 3.74 (m, 1H), 3.73 – 3.60 (m, 3H), 3.50 (t, J = 9.1 970 
Hz, 1H), 3.15 – 3.04 (m, 1H), 2.61 – 2.49 (m, 2H), 2.32 (m, 3H), 1.90 – 1.70 (m, 2H), 1.60-1.50 971 
(m, 9H), 1.42 (s, 12H), 1.33 – 0.96 (m, 79H), 0.90 – 0.68 (m, 30H); 13C NMR (101 MHz, 972 
CDCl3) δ 175.19, 173.13, 137.60, 137.06, 128.79, 128.55, 127.96, 127.92, 126.11, 125.89, 973 
101.41, 101.08, 94.42, 91.90, 81.09, 79.42, 75.24, 74.27, 73.40, 70.88, 68.72, 68.38, 65.83, 974 
62.81, 62.51, 45.55, 45.31, 45.24, 44.92, 41.11, 39.80, 37.56, 35.07, 34.89, 33.90, 31.92, 30.31, 975 
29.77, 29.71, 29.69, 29.67, 29.65, 29.63, 29.55, 29.47, 29.37, 29.36, 29.14, 29.10, 27.82, 27.56, 976 
27.53, 27.51, 27.34, 27.03, 26.37, 24.61, 22.69, 21.39, 21.37, 21.24, 21.10, 20.68, 20.57, 18.54, 977 
17.44, 17.39, 17.31, 17.20, 17.14, 17.11, 16.99, 15.26, 14.11, 14.01, 12.89, 12.64, 12.28, 11.70. 978 
HRMS, calcd for C94H164O15Si2Na (M+Na
+) 1613.154, found 1613.155. 979 
 980 
 981 
16.(2R,4aR,6R,7R,8S,8aR)-6-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-982 
phenylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-7-(palmitoyloxy)-2-983 
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phenylhexahydropyrano[3,2-d][1,3]dioxin-8-yl (2S,4S,6S,8S,10R,12R,14R,16R,17R)-17-984 
hydroxy-2,4,6,8,10,12,14,16-octamethyldotriacontanoate (24): 985 
 986 
 987 
 988 
To compound 23 (167 mg, 0.105 mmol) in THF (4.2 mL) was added TBAF (40 eq, 4.2 mL, 4.2 989 
mmol, 1 M solution in THF, acidified to pH = 6.5 with TFA). The mixture was kept at 40 °C for 990 
24 h and afterwards diluted with EtOAc and the organic layer was washed with 10 mL of water 991 
and then dried over MgSO4. After all volatiles were evaporated, the product was purified using 992 
flash column chromatography (50% EtOAc in pentane) to afford pure 24 (112.1 mg, 79%) as a 993 
colorless oil. [α]D22 = +36.9o (c = 1.3, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.44 (m, 994 
2H), 7.43 – 7.39 (m, 2H), 7.38 – 7.30 (m, 6H), 5.64 (t, J = 9.9 Hz, 1H), 5.51 (s, 1H), 5.50 (s, 995 
1H), 5.40 (d, J = 4.0 Hz, 1H), 5.18 (d, J = 3.8 Hz, 1H), 5.06 (dd, J = 10.0, 4.0 Hz, 1H), 4.32 (dd, 996 
J = 10.2, 5.0 Hz, 1H), 4.24 – 3.98 (m, 3H), 3.85-3.79 (m, 1H), 3.78 – 3.64 (m, 4H), 3.51 (t, J = 997 
9.3 Hz, 1H), 3.47 (br. s, 1H), 2.61 (m, 1H), 2.45 (br. s, 2H), 2.41 – 2.24 (m, 2H), 1.83-1.76 (m, 998 
1H), 1.66 – 1.52 (m, 9H), 1.45 – 1.13 (m, 58H), 1.05 –0.73 (m, 38H); 13C NMR (101 MHz, 999 
CDCl3) δ 175.52, 172.93, 136.94, 136.76, 129.21, 128.87, 128.22, 128.11, 128.09, 126.26, 1000 
125.91, 101.92, 101.19, 94.75, 92.36, 80.84, 79.34, 74.35, 72.20, 71.18, 70.63, 68.63, 68.34, 1001 
63.27, 63.04, 45.52, 45.29, 45.24, 45.11, 41.11, 39.86, 37.60, 35.01, 34.85, 33.88, 31.91, 29.76, 1002 
29.68, 29.66, 29.64, 29.56, 29.50, 29.35, 29.20, 27.95, 27.61, 27.56, 27.52, 27.45, 27.07, 26.34, 1003 
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24.63, 22.68, 21.45, 21.41, 21.22, 21.15, 20.70, 20.51, 18.70, 14.11, 13.96. HRMS, calcd for 1004 
C82H142O14N (M+NH4
+) 1365.043, found 1365.042. 1005 
 1006 
 1007 
17. (2R,4aR,6R,7R,8S,8aR)-6-(((2R,4aR,6R,7R,8S,8aS)-8-hydroxy-2-phenyl-7-(((2,2,2-1008 
trichloroethoxy)sulfonyl)oxy)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-7-(palmitoyloxy)-2-1009 
phenylhexahydropyrano[3,2-d][1,3]dioxin-8-yl (2S,4S,6S,8S,10R,12R,14R,16R,17R)-17-1010 
hydroxy-2,4,6,8,10,12,14,16-octamethyldotriacontanoate (25): 1011 
 1012 
To compound 24 (112 mg, 83 μmol) in DCM (5.5 mL) was added 2,2,2-trichloroethyl sulfuryl 2-1013 
methylimidazolium triflate (2 eq, 76 mg, 0.17 mmol, prepared according to literature)(Ingram et 1014 
al., 2009). The mixture was cooled to 0 °C and 1,2-dimethylimidazole (2.5 eq, 20.0 mg, 0.21 1015 
mmol) was added as solution in DCM (2.5 mL) over 4 h. The reaction was allowed to slowly 1016 
reach rt after which it was stirred for 48 h. The mixture was diluted with DCM and the organic 1017 
layer was washed with brine (10 mL). The organic layer was dried over MgSO4 and all volatiles 1018 
were evaporated. The crude mixture was purified using flash chromatography (15% EtOAc in 1019 
pentane) to afford pure 25 as colorless oil (89.4 mg, 69%). [α]D22 = +39.8o (c = 1.1, CHCl3). 1H 1020 
NMR (400 MHz, CDCl3) δ 7.50 – 7.41 (m, 4H), 7.40 – 7.35 (m, 3H), 7.31 (dd, J = 5.1, 1.9 Hz, 1021 
3H), 5.62 (t, J = 9.9 Hz, 1H), 5.52 (s, 1H), 5.49 (s, 1H), 5.46 (d, J = 3.8 Hz, 1H), 5.36 (d, J = 4.0 1022 
Hz, 1H), 5.08 (dd, J = 10.1, 4.0 Hz, 1H), 5.00, 4.83 (AB system, J = 10.7 Hz, 2H), 4.61 (dd, J = 1023 
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9.6, 3.8 Hz, 1H), 4.43 (dd, J = 10.2, 5.0 Hz, 1H), 4.36 (t, J = 9.5 Hz, 1H), 4.21-4.14 (m, 2H), 1024 
4.02 – 3.89 (m, 1H), 3.72 (t, J = 10.4 Hz, 2H), 3.69 (t, J = 10.4 Hz, 1H), 3.56 (t, J = 9.5 Hz, 1H), 1025 
3.51 – 3.43 (m, 1H), 3.26 (br. s, 1H), 2.71 – 2.47 (m, 1H), 2.35 (t, J = 7.8 Hz, 2H), 1.79 (m, 1H), 1026 
1.66 – 1.49 (m, 9H), 1.47 – 1.07 (m, 68H), 0.84 (m, 30H); 13C NMR (101 MHz, CDCl3) δ 1027 
175.40, 172.75, 136.91, 136.43, 129.48, 128.77, 128.34, 127.99, 126.22, 126.09, 102.24, 101.26, 1028 
94.17, 93.73, 92.49, 81.08, 80.89, 80.02, 79.00, 77.19, 74.34, 70.56, 68.46, 68.36, 68.15, 63.40, 1029 
62.79, 45.52, 45.28, 45.26, 45.17, 41.11, 39.94, 37.60, 34.98, 34.81, 33.83, 31.91, 29.76, 29.69, 1030 
29.66, 29.65, 29.63, 29.55, 29.49, 29.35, 29.21, 29.19, 27.97, 27.63, 27.56, 27.49, 27.12, 26.33, 1031 
24.62, 22.68, 21.50, 21.42, 21.21, 21.16, 20.73, 20.50, 18.67, 14.11, 13.96. HRMS, calcd for 1032 
C84H138Cl3O17S (M−H+) 1555.873, found 1555.873. 1033 
 1034 
 1035 
18. Sodium (2R,3R,4S,5S,6R)-4,5-dihydroxy-2-(((2R,3R,4S,5R,6R)-5-hydroxy-4-1036 
(((2S,4S,6S,8S,10R,12R,14R,16R,17R)-17-hydroxy-2,4,6,8,10,12,14,16-1037 
octamethyldotriacontanoyl)oxy)-6-(hydroxymethyl)-3-(palmitoyloxy)tetrahydro-2H-pyran-2-1038 
yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl sulfate (AM Ac2SGL): 1039 
 1040 
 1041 
To compound 25 (46.7 mg, 0.03 mmol) was added DCM (2 mL) and MeOH (4 mL). Ammonium 1042 
formate (20 eq, 37.8 mg, 0.6 mmol) was added and the mixture was stirred until all ammonium 1043 
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formate dissolved. Pd(OH)2 (0.5 eq, 10 mg, 20% weight on carbon) and Pd/C (0.5 eq, 16 mg, 1044 
10% weight on carbon) was added and the mixture was placed under 1 bar of H2 atmosphere 1045 
(balloon) using three vacuum/N2 cycles followed by four vacuum/H2 cycles. The reaction was 1046 
monitored and after 36 h showed complete disappearance of the starting material. The mixture 1047 
was filtered over Celite, concentrated, the crude was triturated with ether and CHCl3 and the 1048 
supernatant separated carefully with a pipette to get the ammonium salt as a white solid. The 1049 
ammonium salt was flushed over a DOWEX Na+ ion-exchange column (DCM/acetone/MeOH) 1050 
to give the pure sodium salt as a white solid (27.2 mg, 71%). 1H NMR (400 MHz, 1051 
CD3OD/CDCl3) δ 5.47 (d, J = 3.6 Hz, 1H), 5.42 (t, J = 9.8 Hz, 1H), 5.29 (d, J = 3.6 Hz, 1H), 1052 
4.88 (dd, J = 10.2, 3.5 Hz, 1H), 4.19 (dd, J = 9.0, 3.0 Hz, 2H), 3.95 – 3.84 (m, 2H), 3.70 (m, 4H), 1053 
3.59 (t, J = 9.6 Hz, 1H), 3.50 – 3.37 (m, 2H), 2.60 (m, 2H), 2.32 (m, 4H), 1.76 (d, J = 12.3 Hz, 1054 
3H), 1.59 (m, 9H), 1.29 (d, J = 6.6 Hz, 58H), 1.04 – 0.75 (m, 32H); 13C NMR (101 MHz, 1055 
CD3OD/CDCl3) δ 180.57, 176.80, 96.80, 95.87, 80.66, 77.87, 76.64, 76.10, 75.85, 75.22, 74.67, 1056 
74.02, 72.77, 64.82, 64.57, 49.51, 49.33, 49.26, 48.94, 45.41, 44.23, 41.14, 39.10, 38.29, 37.42, 1057 
35.63, 35.61, 33.48, 33.37, 33.36, 33.33, 33.30, 33.28, 33.25, 33.20, 33.04, 33.01, 32.90, 31.85, 1058 
31.63, 31.38, 31.05, 29.88, 28.25, 26.30, 26.28, 24.76, 24.69, 24.51, 24.42, 24.16, 23.87, 21.51, 1059 
17.53, 17.10, 17.08. HRMS, calcd for C68H129O17SNa2 (M+Na
+) 1295.874, found 1295.875. 1060 
 1061 
Generation of SGL-loaded CD1b tetramers. 1062 
Soluble biotinylated CD1b monomers were provided by the National Institutes of Health 1063 
Tetramer Core Facility (Emory University, Atlanta, GA). The loading protocol for CD1b 1064 
monomers was based on previously published glucose monomycolate loading protocols (Kasmar 1065 
et al., 2011). Natural Ac2SGL was dried down in a glass tube in a stream of nitrogen and 1066 
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sonicated into a 50 mM sodium citrate buffer at pH 4, containing 0.25% with 3-[(3-1067 
cholamidopropyl)dimethylammonio] -1-propanesulfonate (CHAPS) (Sigma, St. Louis, MO) for 1068 
1069 
monomer was added and incubated in a 37°C water bath for 2 hours with vortexing every 30 1070 
minute1071 
Tris pH 9. For SL37 Ac2SGL and AM Ac2SGL, the sonication was performed in 50 mM sodium 1072 
citrate buffer at pH 7.4, containing 10 mM taurocholate (Sigma, St. Louis, MO) for 30 minutes at 1073 
37°C. After addition of CD1b, the mixture was incubated in a 37°C water bath for 2 hours. 1074 
1075 
y 10 minutes. The final 1076 
product was filtered through a SpinX column (Sigma, St. Louis, MO) to remove aggregates and 1077 
stored at 4°C until use.  1078 
 1079 
TCR transduction 1080 
TCR constructs containing TCRα and TCRβ separated by a 2A linker were synthesized 1081 
(Biocat, Germany) and inserted into pMIG2 vectors as previously described (Holst et al., 2006). 1082 
Human embryonic kidney (293T) cells were transfected with TCR expression vector, pMIG 1083 
expression vector containing CD3 sequence, packaging vectors pEQ-Pam3(-E) and pVSV-G 1084 
using FuGENE 6 transfection reagent (Promega)(Szymczak et al., 2004). Retrovirus containing 1085 
supernatant was collected twice daily and used to transduce the TCR-deficient T cell line Jurkat 1086 
76 (male) in the presence of Polybrene (Sigma-Aldrich, St. Louis, MO) for a total of 4 days. 1087 
Transduction data are representative of four independent experiments.   1088 
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IFN-γ ELISPOT 1090 
We used an IFN-γ ELISPOT to determine the antigen specificity of our T cell lines. EMD 1091 
Multiscreen-IP filter plates (Millipore, Billerica, MA) were coated with 1D1K antibody 1092 
(Mabtech, Sweden) diluted 1:400 in PBS and incubated overnight at 4˚C. The following day, one 1093 
thousand T cells were plated 1:50 with K562 cells stably transfected with CD1b or with a mock 1094 
vector. Lipids antigens were stored in 2:1 chloroform:methanol and appropriate amount was 1095 
dried using gaseous nitrogen. The lipids were sonicated into media to obtain a 4 µg/mL 1096 
suspension and plated with the cells at a final concentration of 1 µg/mL. These cultures were 1097 
incubated at 37˚C for approximately 16 hours. The following day, the cells were washed twice 1098 
with sterile water to lyse the cells, and the plates were incubated with the detection antibody 7-1099 
B6-1-biotin (Mabtech, Sweden) diluted 1:1000 in PBS + 0.5% FCS and incubated for two hours 1100 
at room temperature. The cells were then washed five times with PBS and incubated in 1101 
ExtrAvidin-Alkaline Phosphatase (Sigma, St. Louis, MO) diluted 1:1000 in PBS and incubated 1102 
for one hour at room temperature. The wells were then washed five times and incubated with 1103 
BCIP/NBT substrate (Sigma, St. Louis, MO) for five minutes to develop the membrane. The 1104 
wells and IFN-γ spots were counted using an ImmunoSpot S6 Core Analyzer (Cellular 1105 
Technology Limited, Cleveland, OH). ELISPOT assay results are reported as the mean of 1106 
triplicate wells. Representative data was shown from at least two independent replicates.  1107 
 1108 
T cell receptor sequencing 1109 
High-throughput sequencing of TCRs of cell line A01 was performed using the 1110 
ImmunoSEQ assay (Adaptive Biotechnologies, Seattle, WA) with TCR- and/or TCR- 1111 
assays for each sample using a multiplex PCR approach following by Illumina high-throughput 1112 
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sequencing (Robins et al., 2010; Carlson et al., 2013).  The TCRs of C56SL37 and C58SL37 1113 
were sequenced by a single cell approach (Wang et al., 2012). 1114 
 1115 
Production of wild-type and mutant CD1b-expressing C1R cells. 1116 
Gene segments encoding full-length wild-type CD1b or single-site mutant CD1b (E62A, E65A, 1117 
I69A, R71A, V72A, F75A, R79A, E80A, D83A, Q150A, Y151A, E156A, I160A, E164A, 1118 
T165A and R168A) were purchased from Thermo Fisher Scientific (Waltham, MA), cloned into 1119 
the pMIG retroviral vector and transfected into HEK293T (female) cells to produce CD1b 1120 
containing retrovirus. C1R (female) cells were transduced with retroviral supernatants as 1121 
previously described (Birkinshaw et al., 2015). Each of the CD1b transduced cell lines were 1122 
stained with an anti-CD1b monoclonal antibody (SN13; Biolegend, San Diego, CA) and sorted 1123 
by flow cytometry with a FACSAria III Cell Sorter (BD Biosciences, San Jose, CA) to ensure 1124 
each line expressed similar levels of CD1b. Data are representative of three independent 1125 
experiments with triplicate wells. Error bars represent SEM of triplicate wells.  1126 
 1127 
QUANTIFICATION AND STATISTICAL ANALYSIS 1128 
Error bars reported represent the standard error of the mean (SEM) or standard deviation (SD), as 1129 
reported in the Figure legends. SEM and SD were calculated using GraphPad Prism (v.6.0).  1130 
Estimated EC50 values were calculated based on a nonlinear regression model of the means of 1131 
triplicate wells in GraphPad Prism (v.6.0). Our data do not violate assumptions of the non-linear 1132 
regression model. Information regarding experimental replicates can be found in the Methods 1133 
subheading of STAR Methods.   1134 
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KEY RESOURCES TABLE  
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-CD3 (UCHT1) Beckman Coulter Cat #: A07748 
Mouse monoclonal anti-CD1b (SN13) Biolegend Cat #: 329108 
Mouse monoclonal anti-CD4 (13B8.2)  Beckman Coulter Cat #: A94685 
Chemicals, Peptides, and Recombinant Proteins 
Recombinant IL-2 Prometheus Pharmaceuticals N/A 
Phytohaemagglutinin (PHA) Thermo Fisher Scientific Code: R30852801 
Natural IL-2 Hemagen List #: 906011 
Critical Commercial Assays 
Human IFN-γ ELISpot BASIC (ALP) Mabtech Cat #:3420-2A 
Experimental Models: Cell Lines 
Human: C1R CD1b Mutant Transfectants This manuscript N/A 
Human: K562 CD1b Transfectants de Jong et al. 2014 N/A 
Human: HEK293T ATCC ATCC Cat #:CRL-3216 
Recombinant DNA 
pMIG2  Holst et al. 2006 N/A 
pEQ-Pam3(-E)  Holst et al. 2006 N/A 
pVSV-G Holst et al. 2006 N/A 
Software 
Prism (v6.0) GraphPad http://www.graphpad.com 
FlowJo (v9.7) FlowJo, LLC  https://www.flowjo.com 
Other 
Streptavidin, crosslinked, conjugate Thermo Fisher Scientific Cat #: S868 
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